Journal of **Medicinal** Chemistry


Discovery of (2S)-1-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1one (MPC-3100), a Purine-Based Hsp90 Inhibitor

Se-Ho Kim,* Ashok Bajji, Rajendra Tangallapally, Benjamin Markovitz, Richard Trovato, Mark Shenderovich, Vijay Baichwal, Paul Bartel, Daniel Cimbora, Rena McKinnon, Rosann Robinson, Damon Papac, Daniel Wettstein, Robert Carlson, and Kraig M. Yager*

Myrexis Inc., 305 Chipeta Way, Salt Lake City, Utah 84108, United States

Supporting Information

ABSTRACT: Modulation of Hsp90 (heat shock protein 90) function has been recognized as an attractive approach for cancer treatment, since many cancer cells depend on Hsp90 to maintain cellular homeostasis. This has spurred the search for small-molecule Hsp90 inhibitors. Here we describe our lead optimization studies centered on the purine-based Hsp90 inhibitor 28a containing a piperidine moiety at the purine N9 position. In this study, key SAR was established for the piperidine N-substituent and for the congeners of the 1,3benzodioxole at C8. These efforts led to the identification of orally bioavailable 28g that exhibits good in vitro profiles and a characteristic molecular biomarker signature of Hsp90 inhibition both in vitro and in vivo. Favorable pharmacokinetic



properties along with significant antitumor effects in multiple human cancer xenograft models led to the selection of 28g (MPC-3100) as a clinical candidate.

INTRODUCTION

Heat shock proteins (HSPs) are some of the most abundant intracellular proteins and play critical roles as molecular chaperones in essential cellular functions such as (1) protein maturation, folding, and prevention of aggregation, (2) sorting and translocation, (3) stabilization of proteins involved in signal transduction, and (4) apoptosis and proteasomal degradation.¹⁻³ Hsp90 is one of the major HSPs and exists as a homodimer. Each monomer is composed of three domains: an N-terminal ATP-binding domain, a middle domain, and a Cterminal dimerization domain.^{4,5} Hsp90 is unique among HSPs because it associates with cochaperones (e.g., Hsp70, Hsp40, cdc37, p23) to form a multichaperone complex that interacts with a large number of cofactors (e.g., HIP, HOP, immunophilins). Because Hsp90 is ubiquitously expressed in both normal and tumor tissue, it was believed that inhibition of the Hsp90 pathway would affect normal cellular function and lead to general toxicity. As a consequence, Hsp90 was not immediately recognized as a viable target for cancer treatment.⁶ Evidence supporting the therapeutic potential of Hsp90 inhibition was provided by reports that Hsp90 is overexpressed in numerous cancer cell types.7 However, direct evidence for Hsp90 therapeutic value came from the observation that v-Srcmediated transforming activity was abolished by the natural product geldanamycin (1a) via disruption of Src-Hsp90 protein complexes.⁸ This seminal work revealed a critical role of the Hsp90 chaperone machinery in the stability of v-Src and also showed that c-Src is less affected than v-Src by inhibition of Hsp90. Since then, over 200 proteins, known collectively as client proteins, were found to depend on the Hsp90 system for their function and stability and most of these client proteins are involved in signal transduction, including kinases (e.g., Her2, AKT, Bcr-Abl, Cdk4, B-raf), hormone receptors (e.g., androgen, estrogen, glucocorticoid receptors), and transcription factors (e.g., mutant p53, HIF-1 α). Importantly, many of these are involved in oncogenesis and contribute to the six well-defined hallmarks of cancer.⁹ Not surprisingly, a number of Hsp90 client proteins have received attention as potential targets for cancer therapy, and this approach has been successful.¹⁰ However, the development of drug resistance resulting from target kinase mutations, feedback signaling loops, and alternative survival pathway activation has become a significant therapeutic challenge.¹¹ In contrast, the simultaneous targeting of multiple signaling pathways via inhibition of the Hsp90 chaperone system has the potential to be both more efficacious and less vulnerable to resistance mechanisms.¹² An important aspect of Hsp90 as a cancer target is the differential effect of Hsp90 inhibitors on cancer cells. In animal models, several different Hsp90 inhibitor classes have shown selective

Received: April 2, 2012

pharmacology in tumor cells and strong anticancer effects at nontoxic levels. Although a complete understanding of the origins of selectivity requires additional studies, mounting evidence suggests that oncogene addiction,^{3,13} synthetic lethality,¹⁴ activation,¹⁵ and post-translational modification of Hsp90 in tumors might account for this unique observation.^{16,17}

In contrast to cancer, where Hsp90 inhibition is sought, induction of Hsp90 activity has been proposed as a potential treatment for neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (Lou Gehrig's disease). These diseases are associated with accumulation of misfolded proteins, which are toxic to neuronal cells. It has been suggested that enhancing protein-folding capacity by pharmacological activation of transcription factor heat shock protein 1 (HSF1) could be a promising strategy for the treatment of neurodegenerative diseases. Paradoxically, because of feedback regulation, Hsp90 inhibitors induce Hsp90 protein levels via HSF1 activation and therefore may have utility in the treatment of neurodegenerative diseases.

Taken together, it is now evident that Hsp90 is a bona fide cancer target, and the development of Hsp90 inhibitors has become one of the most active areas of research not only for cancer chemotherapy but also potentially for treatment of neurodegenerative disease.

Sixteen Hsp90 inhibitors have entered clinical development as novel anticancer agents.^{20–25} All of these inhibitors target the N-terminal, ATP-binding site of Hsp90 and effectively block the essential ATPase activity. The first-in-class inhibitor, 17-AAG (1b), a geldanamycin analogue with improved pharmacological properties over the parent geldanamycin, is being evaluated in phase II-III clinical trials by several sponsors (Figure 1). However, 17-AAG (1b) presents significant barriers to development, including poor aqueous solubility, Pglycoprotein (P-gp) multidrug resistance efflux pump substrate activity, limited oral bioavailability, and hepatotoxicity which is believed to be a consequence of its benzoquinone moiety and the formation of a drug-glutathione (GSH) adduct upon redox activation.^{26,27} The more water-soluble geldanamycin analogues 17-DMAG (1c) and IPI-504 (1d), a prodrug of 17-AAG (1b), have solved some of the aforementioned limitations and are being evaluated in clinical trials.²⁰ Radicicol (2a) is a resorcinolcontaining natural product inhibitor of Hsp90.²⁸ Because of its potent Hsp90 inhibition and resultant antiproliferative activity in cells, this natural product has garnered widespread interest in the synthetic community, and several total syntheses have been reported.²⁹ However, lack of potency in animal models, believed to be a result of the reactive epoxide and 1,6-dienone moieties, has precluded further development. Efforts to modify the radicicol (2a) core, specifically by replacement of the epoxide ring and attenuation of the 1,6-dieneone reactivity, have led to the identification of more stable cyclopropyl- (2b) and oxime-radicicol analogues 3a,b with improved in vitro potency.^{25,28,29} These compounds, however, remain in the preclinical development stage. As a way of overcoming the limitations presented by natural product Hsp90 inhibitors, synthetic hybrids³⁰ of geldanamycin (1a) and radicicol (2a) have been developed with the aid of structure-based drug design, and the chimeric inhibitors, radester (4) and radanamycin (5), are promising new leads.^{25,31}

The identification and optimization of entirely synthetic, small molecule inhibitors of Hsp90 have been undertaken by several research groups as a way of imparting more druglike




Figure 1. Natural product and natural-product-derived Hsp90 inhibitors.

properties (Figures 2 and 3). The first synthetic Hsp90 inhibitor, purine derivative PU3 (7), originated from the Chiosis laboratory³² and was designed to bind the N-terminal ATP-binding pocket of Hsp90. PU3 (7) adopts the C-type conformation reminiscent of geldanamycin (1a), and subsequent structure-based optimization resulted in the discovery of the potent, water-soluble inhibitor PU-H71 (8),³³ currently being evaluated in phase I clinical trials.²⁰ A similar purinebased inhibitor 9 was developed by Conforma Therapeutics (now Biogen Idec).³⁴ A common structural feature of the optimized purine-based inhibitors 8 and 9 is the sulfur atom tethering the purine C8 position and the substituted aryl ring. The PU class $(6)^{32}$ has received attention by several research groups and has served as a guide for design of new Hsp90 inhibitors. Key PU-class structural features were utilized during the design of BIIB021 (10).35 In this instance, however, binding elements were rationally and systematically "rotated" around the purine ring, resulting in a unique purine derivative in which the aryl group is connected via the N9 position as opposed to the N8 position. BIIIB021 (10) was advanced into phase I-II clinical trials. Finally, several synthetic non-purine small molecules 15-20 encompassing diverse structural features have been identified through HTS, fragment-based, and structure-based drug design approaches,^{20-24,36,37} and these inhibitors are being evaluated in clinical settings (Figure 3).

We believed that the inherent activity of the purine scaffold, in concert with new synthetic methodologies, would provide a good starting point for the synthesis of novel analogues,³⁸ and as such, our Hsp90 drug discovery program was also based on





Figure 2. Selected purine-based and purine-like Hsp90 inhibitors.

the PU class. A shared feature of the majority of purine-based inhibitors (Figure 2) is the presence of pendent hydrophilic N9 substituents. This modification, intended to improve aqueous solubility and other physical properties, demonstrated the utility of the N9 substituent for modulation of molecular properties. Similarly, we investigated the effects of various N9 substituents on ligand potency and ADME properties. Herein we report a novel series of purine-based Hsp90 inhibitors, their synthesis via new C–S bond formation methodology, and the biological evaluations leading to the identification of **28g** (MPC-3100) as a phase I clinical candidate.³⁹

CHEMISTRY

Synthetic routes for preparation of 9-*N*-alkyl-8-arylsulfanyladenines **23** are categorized into two classes (Scheme 1).^{32,40}



Method A involves a two-step procedure consisting of Cu(I)catalyzed coupling of 8-mercaptoadenine (21) with aryl iodides (ArI),⁴¹ followed by N-alkylation with alkyl halides or mesylates (RX).³³ Alkylation typically resulted in a ~2: 1 mixture of N9 and N3 regioisomers. Alternatively, aryldiazonium salts (ArN₂X) could be used instead of aryl iodides (ArI) as coupling partners during C–S bond formation.⁴² Method B utilizes N-alkylbromoadenines **22**, which can be prepared regioselectively in high yields.^{34,43} Displacement of the bromide in **22** with arylthiols (ArSH) proceeds under mild conditions to provide **23** as single regioisomers. A significant drawback to method B, however, is the propensity of arylthiols toward disulfide formation.

The synthetic approach for our initial SAR studies was based on method A. However, instead of utilization of difficult to source aryl iodides, more readily available aryl bromides were desirable, and as a consequence, a Pd(0)-catalyzed coupling of 8-mercaptoadenine $(21)^{42}$ with aryl bromides 24a-g (Scheme 2) was developed using catalytic Pd₂dba₃, the ligand xantphos, a base (K₂CO₃ or Cs₂CO₃) in dioxane. For the Pd-catalyzed reaction, we chose ortho-substituted aryl bromides 24a-g (X = Br, CN) as coupling partners, since early SAR studies revealed the critical nature of the 8-aryl group ortho-substituent (X) for





Figure 3. Selected examples of structurally diverse non-purine Hsp90 inhibitors.


Scheme 2^{*a*}



"Reagents and conditions: (a) 24a-g, Pd_2dba_3 , xantphos, K_2CO_3 , dioxane, 100 °C, 15-45%; (b) **25b**, Barton's base, 80 °C, DMF, 20-51%.

Hsp90 inhibition.^{43,58} This synthetic approach eliminates the need for installation of the key ortho-substituent at a later stage. Although yields were modest, this approach allowed the use of readily available ortho-substituted aryl bromides 24a-g and was used to prepare key intermediates 26a-g in a rapid fashion. Moreover, the coupling of aryl dibromides 24a-f(X = Br) with 21 proceeded without formation of undesired bis-arylsulfanyl products. With 8-arylsulfanyladenines 26a-g in hand, alkylation with 25b was carried out in the presence of Barton's base. The desired N9 regioisomers 28a, 34g, 34n, 34f, 34l, 34m, and 34q were obtained in 20-51% yield after removal of the minor N3 regioisomers (structures not shown) by silica gel chromatography or preparative scale RP-HPLC. In a similar manner, analogues 27a and 27c-i were synthesized using 25a and 25c-i as alkylating agents. The N-Boc group of 27a was removed using TFA, and the resulting free piperidine analogue 27b was converted into N-acylpiperidine analogues 28a-j and 28n via EDCI-mediated coupling with the appropriate carboxylic acid (step c, Scheme 3). Incorporation of N-Boc protected amino acids in the EDCI coupling sequence afforded **28k** and **28l-o** (step d, Scheme 3).

The synthesis of **25a**–**i** is shown in Scheme 4. Compounds **30a**,**b** are commercially available or can be conveniently prepared from **29** by *N*-Boc protection or N-formylation, respectively. Mesylation of the resulting alcohols **30a**,**b** afforded compounds **25a**,**b**. Reductive alkylation^{44,45} of **29** with acetone, isobutyraldehyde, or cyclohexanecarboxaldehyde provided **30c**,**d**,**f** which were then converted to the mesylates **25c**,**d**,**f**.




"Reagents and conditions: (a) **25a** or **25c**-i, Barton's base, 80 °C, DMF, 20–51%; (b) TFA, CH_2Cl_2 , rt, >90%; (c) EDCI, HOBt, DMF, R_2CO_2H (R_2 = H, CH_3 , propyl, cyclopropyl, cyclopentyl, CH_2OH , (S or *R*)-CH(OH)CH₃, C(CH₃)₂OH, acetyl, $CH_2N(CH_3)_2$); (d) EDCI, HOBt, DMF–THF, rt, R_2CO_2H (R_2 = (S)-CH(CH₃)NHBoc, (S)-CH(*i*Bu)NHBoc, C(CH₃)₂NHBoc or *N*-Boc-L-proline), then 4 M HCl or TFA.

Alternatively, N-alkylation of **29** with the appropriate alkyl halide could also be used to prepare these intermediates. N-Alkylation of **29** with CF₃CH₂I or propargyl bromide under the standard procedure⁴⁶ followed by mesylation afforded **25e** and **25g**. Synthesis of tetrazole derivatives **25h**,i was achieved employing known synthetic methods.⁴⁷ Finally, thioureas **31a** and **31b**, derived from **29** and methyl- or *tert*-butyl isothiocyanate, were converted to tetrazoles **25h**,i with NaN₃ and HgCl₂ followed by tosylation.


Although method A proved adequate for initial SAR studies, separation of the undesired N3 regioisomers and low overall yields presented major hurdles to more extensive SAR studies. Therefore, method B (Scheme 1) was adopted for synthesis of later-stage targets. N9-substitued bromoadenines 33a,b were readily prepared in high overall yield by literature proce-dures.^{34,43} The reaction sequence involved alkylation of adenine (32) with alkylating agents 25a,b (Scheme 7) and bromination in acetic acid buffer. During the alkylation step a small amount (<10%) of N3 isomers were produced but were easily removed by trituration after the bromination step. Our strategy for the synthesis of arylthiols (ArSH) utilized 3ethylhexyl 3-mercaptopropanoate (52, Scheme 5),⁴⁸ a known thiol surrogate, as a means of preventing oxidative disulfide formation of the arylthiol intermediates. The synthetic utility of 52 as a thiol surrogate has been demonstrated previously for synthesis of benzothiazoles and biaryl compounds,48b,c and a similar strategy has been applied to the synthesis of aryl sulfoxides.⁴⁹ Described below is the successful application of the thiol surrogate strategy to the synthesis of structurally diverse 9-N-alkyl-8-arylsulfanyladenines (Schemes 5-9).

Scheme 4^{*a*}




"Reagents and conditions: (a) Boc₂O, NEt₃, CH₂Cl₂; (b) HCO₂Me, NaOH, MeOH; (c) acetone, *i*-Bu-CHO, or *c*-Hex-CHO, NaBH(OAc)₃, CH₂Cl₂ (or NaCNBH₃, AcOH, MeOH–THF); (d) CF₃CH₂I, K₂CO₃, CH₃CN, reflux or CF₃CH₂OMs, NEt₃, THF; (e) propargyl bromide, Hünig's base, THF; (f) MsCl, or TsCl, NEt₃ (or DMAP), CH₂Cl₂, rt, 30–95%; (g) SCN-Me or SCN-*t*-Bu, CH₂Cl₂, rt, 80–85%; (h) NaN₃, HgCl₂, NEt₃, DMF, 41–50%.





"Reagents and conditions: (a) **52**, Pd₂dba₃ (5–10 mol %), xantphos (10–20 mol %), Hünig's base, dioxane, 100 °C, 10 h, >80%; (b) NBS, HBF₄·Et₂O, AcCN, -15 to 5 °C, >70%; (c) DDQ, 1,4-dioxane, 100 °C, ~90%.

The detailed reaction sequence for synthesis of aryl sulfides is given in Scheme 5. Aryl sulfides 43a-c were prepared in a single step using a Pd(0)-catalyzed coupling of aryl dihalides 24a,b and 41 with 52. Compounds 43a,b could also be obtained from aryl bromides 42a,b via a two-step procedure involving Pd(0)-catalyzed coupling and ortho-bromination.⁵⁰ Synthesis of aryl sulfide 45 was achieved in two steps from the known bromodihydrobenzofuran 44^{51} via Pd(0)-catalyzed coupling of 52 and subsequent ortho-bromination. Oxidation of dihydrobenzofuran 45 with DDQ afforded benzofuran 46. An identical procedure was applied to the synthesis of 48a, a regioisomer of 45, using commercially available 5-bromo-2,3dihydrobenzofuran (47). In the instances of aryl sulfides 48a and 48b, nonselective bromination afforded ~1:3 mixtures that were oxidized directly with DDQ to provide benzofurans 49a and 49b; the undesired regioisomers were removed by preparative RP-HPLC upon reaction with bromoadenine 33. Similarly, aryl sulfide 51 was obtained from 50 using the twostep sequence of Pd(0)-catalyzed coupling with 52 and orthobromination. With the requisite aryl sulfides **35** in hand, the stage was set for the critical C–S bond forming reaction (Scheme 6). To this



end, a solution of aryl sulfide 35 in THF was treated with NaOEt (2.2 equiv) and the resulting mixture was stirred at ambient temperatures for 2 h. After concentration to drvness, the crude sodium arylthiolate salt (ArSNa, 35-Na) was diluted with a mixture of THF and ethanol (10/1, v/v), combined with bromoadenine 33a (or 33b), and heated at 60-65 °C for several hours. The reaction proceeded cleanly to yield product 37 in moderate to good yield after silica gel chromatography. Concentration of the sodium arylthiolate mixture before addition of 33a.b is crucial for maximizing the yield of 37. Otherwise, 37 further reacts with ethyl acrylate 36 (Alk = Et), generated via β -elimination of 35 and transesterification with ethanol, through an aza-Michael reaction resulting in the formation of varying amounts of side product 38. By use of this protocol, aryl sulfides 43a-c, 45, 46, 48, 49, or 51 were converted to the corresponding sodium thiolates (ArSNa), which upon reaction with bromoadenine 33b afforded Nformylpiperidine analogues 28a, 34a, 34c, 34d, 34e, 34g, 34k, and 340 in good yields under mild conditions (Scheme 7). Intermediates 27a and 39a-d were prepared from 33a in a similar fashion (Scheme 8). Deprotection of 27a and 39a-d with TFA gave piperidine intermediates 27b and 40a-d, respectively, which were conveniently transformed into target molecules 28a, 28f-h, 34b, 34g-j, and 34p via EDCImediated coupling with appropriate carboxylic acids (Scheme 9).


A scalable, straightforward, and chromatography-free procedure for the preparation of **28a** and **28f**-**h** was also developed. By employment of the stable and readily available 1,3benzodioxole-5-thiol (**53**), displacement of bromoadenine **33a** followed by bromination with NBS provided **27a**. After removal of the Boc group, **27b** could be converted into **28a** and **28f**-**h** by EDCI coupling with the appropriate carboxylic acid (Scheme 10).

RESULTS AND DISCUSSION

We began our study⁵² by looking for a replacement for the N9 propargyl moiety present in inhibitor 54^{43} developed by the Chiosis group. Since phenyl groups can serve as bioisosteres of propargyl groups,⁵³ analogue 55b (n = 2) was initially prepared and the in vitro potency was compared to other analogues having various alkyl chain lengths (zero to three carbon atoms). Consistently, phenethyl analogues 55a (n = 1) demonstrated 3-


Scheme 7^a

Article




^aReagents and conditions: (a) **25a** or **25b**, Cs₂CO₃, DMF, rt, 16 h, ~80%; (b) Br₂, NaOAc–AcOH (pH 4.6), MeOH/THF, rt, 2 h, ~67%; (c) **43a–c**, **45**, **46**, **48**, **49**, or **51**, NaOEt, THF/EtOH (10/1, v/v), 60 °C, 3–10 h, 35–80%.

Scheme 8^{*a*}




^aReagents and conditions: (a) 43a-c, 45, 51, NaOEt, THF/EtOH (10/1, v/v), 60 °C, 3–10 h, 35–80%; (b) TFA or 4 M HCl in dioxane, CH₂Cl₂, rt, >90%.

to 6-fold more potent activity than homologues (e.g., **55b**) in the Hsp90 FP (fluorescence polarization) assay. With the twocarbon linking element considered optimal, varying substituents on the aromatic ring were explored, and it was found that electron-withdrawing groups (R = 2'-F, 2'-Cl, 2'-Br) at the aryl 2'-position were most potent giving IC₅₀ values in the range



^aReagents and conditions: (a) EDCI, HOBt, DMF–THF, R₂CO₂H (R₂ = H, CH₂OH, (S or R)-CH(OH)CH₃), rt, 10 h, 55–93%.






"Reagents and conditions: (a) K_2CO_3 , DMF, 120 °C, 16 h, 94%; (b) NBS, AcOH, rt, 73%; (c) TFA, CH_2Cl_2 , rt, >90%; (d) EDCI, HOBt, DMF, R_2CO_2H ($R_2 = H$, CH_2OH , (S or R)-CH(OH)CH₃), rt, 10 h, 55–93%.

30-50 nM in the Hsp90 FP assay. Potency in both the Her2luciferase degradation and HCT116 antiproliferative assays was commensurate with the Hsp90 FP assay potencies (IC₅₀^{FP} = 0.04-0.05 μ M; IC₅₀^{Her2} = 0.05-0.16 μ M; IC₅₀^{HCT116} = 0.2-0.5 μ M). However, metabolic stability (<1% parent drug remaining after 40 min of incubation with human liver microsomes (HLM)) was found to be a significant liability for these derivatives. Several structural modifications to the pendent aryl group were explored as a means of improving metabolic stability: blocking potential metabolic sites on the aromatic ring and/or benzylic position, reducing log P by incorporation of heteroaromatic ring systems (for example, pyridine, pyrrole, and imidazole), and bioisosteric substitution of the phenyl ring with thiophene. Unfortunately, none of these modifications proved to be successful and in most cases resulted in a significant potency loss, and consequently a suitable replacement for the phenethyl system was sought. To this end, the aryl moiety was replaced with an aminomethylcyclopropyl group

 $(55 \rightarrow 56$, Scheme 11). Since increasing the cycloaliphatic ring size and modifications to the amino group failed to improve


Scheme 11



potency ($IC_{50}^{FP} = 0.08 \ \mu$ M), the PK properties of aminomethylcyclopropyl analogue **56** were evaluated. Despite vastly improved water solubility (>100 μ M at pH 7.4 in phosphate buffer) and metabolic stability, **56** demonstrated unacceptably poor PK including high clearance rates and extremely low oral bioavailability (*F* = 0.4%), presumably a consequence of low cellular permeability.

Efforts to improve oral bioavailability, while preserving inhibitory activity, led to replacement of the aminomethylcyclopropyl moiety in **56** with a 4-piperidine ring (**56** \rightarrow **28a**, Scheme 11). As part of this strategy, *N*-formyl analogue **28a** was prepared and evaluated for both inhibitory potency and PK properties; the oral bioavailability was much improved (*F* = 35%) and the potency was acceptable (IC₅₀^{FP} = 0.15 μ M; IC₅₀^{Her2} = 0.08 μ M; IC₅₀^{HCT116} = 0.43 μ M). The piperidine group has been frequently utilized during lead identification and optimization⁵⁴ and in this instance resulted in improved oral bioavailability while providing a versatile platform for the design of new analogues. Along these lines, subsequent work was focused on variations on the piperidine N-substituent with the ultimate goal of improving potency and ADME properties.

Unsubstituted piperidine analogue **27b** and *N*-alkyl substituted analogues **27c**–**f**, where R₁ is *i*-Pr, *i*-Bu, CH₂CF₃, CH₂*c*-Hex, respectively, were prepared, and their potency was evaluated in the Hsp90 FP assay. As shown in Table 1, this modification resulted in diminished activity compared to **28a** (IC₅₀^{FP} = 0.15 μ M), with IC₅₀^{FP} values of 0.47, 0.90, 0.70, 0.60, and 0.24 μ M, respectively. On the other hand, *N*-propargyl analogue **27g** displayed similar biochemical (IC₅₀^{FP} = 0.11 μ M) and cellular potencies (IC₅₀^{Her2} = 0.10 μ M vs 0.07 μ M and



Cmpd	Rı					
		FP ^a	Her2 ^a	HCT116 ^a	NCI-ADR- RES ^a	^b HLM(%)
28a	СНО	0.15	0.07	0.43	2.8	17
27b	Н	0.47	0.95	4.6	>100	78
27c	iPr	0.90	0.32	2.58	7.25	nd ^c
27d	iBu	0.70	0.11	nd	1.98	nd
27e	CH ₂ CF ₃	0.60	nd	nd	nd	nd
27f	CH ₂ - <i>c</i> Hex	0.24	0.25	1.00	0.722	10
27g	CH ₂ -CCH	0.11	0.10	0.74	0.70	10
27h	$H_{3C}^{N \sim N}$	0.045	0.031	0.062	0.13	0
27i		1.8	nd	nd	nd	nd

"Average of at least two experiments. Assay error for FP is $\pm 10\%$ and $\pm 30\%$ for remaining assays." Metabolic stability in human liver microsomes; percent parent remaining after 40 min of incubation. "Not determined.


 $IC_{50}^{HCT116} = 0.74 \ \mu M \text{ vs } 0.43 \ \mu M$, for 27g and 28a) to 28a, but poor predicted metabolic stability (HLM = 10%) precluded its further evaluation in animals. As part of this SAR study, compound cytotoxicity was also determined on the drugresistant ovarian tumor cell line NCI-ADR-RES, which overexpresses the P-glycoprotein 1 (P-gp1) drug efflux pump relative to the drug-sensitive parental cell line OVCAR8, which lacks P-gp1 overexpression. Compound potency, as determined by cytotoxicity using the drug-sensitive cell lines HCT116 or OVCAR8, was always similar. As a result, comparison of the cytotoxic potency between NCI-ADR-RES and HCT116 or OVCAR8 was used to indicate whether a test compound was a substrate for the P-gp1 drug efflux pump. Cytotoxicity in the NCI-ADR-RES system was found to be dependent on the steric bulk and lipophilicity of the piperidine nitrogen substituent and on the presence of a hydrogen bond donor atom.⁵⁵ Whereas cyclohexylmethyl and propargyl analogues 27f,g were equipotent in both the HCT116 and NCI-ADR-RES assays, the free piperidine analogue 27b lost complete potency in the latter assay (IC₅₀^{NCI-ADR-RES} \geq 100 μ M). Similarly, isopropyl analogue 27c showed a 2- to 3-fold decreased cytotoxicity in NCI-ADR-RES relative to HCT116. For tetrazole analogues 27h and 27i, the size of the N-alkyl group impacted inhibitory activity; Nmethyltetrazole 27h exhibited potent inhibitory activity in both the biochemical $(IC_{50}^{FP} = 0.045 \ \mu M)$ and cell-based assays $(IC_{50}^{Her2} = 0.031 \ \mu M; IC_{50}^{HCT116} = 0.062 \ \mu M; IC_{50}^{NCI-ADR-RES} =$ 0.13 μ M), whereas *N*-tert-butyltetrazole, 27i, lost significant activity in the FP binding assay (IC₅₀^{FP} = 1.8 μ M).

Unfortunately, the poor metabolic stability of **27h** precluded further evaluation. Thus, further SAR studies were undertaken via synthesis of *N*-acylpiperidine analogues **28a–o** (Table 2).

As part of this study, other N9 heterocyclic systems were also explored with representative examples illustrated in Scheme 12. The position of the piperidine nitrogen and ring size were modified resulting in 3-piperidine 62, 2-piperidine 63, and 3pyrrolidine 64 analogues that were similar to, or slightly less potent than, the corresponding 4-piperidine analogues (e.g., 63, R = CHO, $IC_{50}^{FP} = 0.18 \ \mu M$ for the S-isomer, $IC_{50}^{FP} = 0.19$ μ M, for the R-isomer; **28a**, IC₅₀^{FP} = 0.15 μ M). The 4tetrahydropyran derivative **65** showed potency comparable to that of **28a** in the three main assays ($IC_{50}^{FP} = 0.057 \ \mu M$; $IC_{50}^{Her2} = 0.09 \ \mu M$; $IC_{50}^{HCT116} = 0.59 \ \mu M$). Not surprisingly, however, 65 demonstrated very low metabolic stability (HLM = 0%), likely a result of oxidative ring cleavage.⁵⁶ In an attempt to improve the metabolic stability of 65, the known⁵⁷ ether bioisostere gem-difluorocyclohexane was incorporated providing 66. This modification resulted in modestly improved metabolic stability (HLM = 15%) but with concomitant loss in potency $(IC_{50}^{FP} \approx 1.0 \ \mu M)$. The oxa- and aza-bicyclic heterocyclic analogues 67a,b, possessing carbon atoms adjacent to the heteroatoms, were also explored as a means of improving the metabolic stability of 65. And while they were similar in potency to 65, no improvement in metabolic stability was realized.

For continuation of SAR studies surrounding N-acyl analogues **28a**-**o**, three types of R_2 substituent were examined

Article




"Average of at least two experiments. Assay error for FP is $\pm 10\%$ and $\pm 30\%$ for remaining assays. ^bMetabolic stability in human liver microsomes; percent parent remaining after 40 min of incubation. ^cNot determined.

(Table 2): (1) alkyl or cycloalkyl groups (**28b–e**); (2) alkyl or cycloalkyl groups containing an oxygen functionality (**28f–j**); (3) alkyl or cycloalkyl groups containing an amine functionality (**28k–o**). In the alkyl and cycloalkyl series, alkyl chain length and the ring size were both investigated. Conversion of the formyl group (**28a**, R₂ = H) to an acetyl (**28b**, R₂ = CH₃) resulted in no significant change in potency. Increasing the carbon chain length reduced potency ~2 fold (IC₅₀^{FP} = 0.15 vs 0.29 μ M and IC₅₀^{HCT116} = 0.43 vs 0.85 μ M, **28a** and **28c**, respectively), and the cyclopropyl analogue **28d** demonstrated potency comparable to that of the lead **28a** in biochemical and cell-based assays. Additionally, **28d** was not a MDR substrate as indicated by equipotency in the NCI-ADR-RES assay, but again, metabolic instability in human microsomal assays

obviated further progression of this otherwise promising inhibitor. Inhibitory potency was found to decrease with increasing ring size as illustrated by cyclopentyl analogue **28e**, which was 2- to 3-fold less potent (IC₅₀^{FP} = 0.25 μ M; IC₅₀^{Her2} = 0.25 μ M; IC₅₀^{HCT116} = 1.3 μ M) than the lead **28a**. Incorporation of a primary or secondary hydroxyl group into the R₂ substituent improved metabolic stability (HLM = 42– 58% for **28f-h**) while maintaining potency (IC₅₀^{FP} = 0.11– 0.14 μ M; IC₅₀^{Her2} = 0.06–0.09 μ M; IC₅₀^{HCT116} = 0.38–0.64 μ M). No significant differences in potency and metabolic stability were observed among the hydroxyl substituted analogues as a group. Although this modification resulted in a moderate decrease in NCI-ADR-RES cytotoxicity, possibly due to hydrogen bonding capacity, they were advanced into PK

Scheme 12



evaluations given the improved balance between potency and microsomal stability. Interestingly, gem-dimethyl derivative **28i** lost all binding potency (IC₅₀^{FP} \geq 5 μ M). Propane-1,2-dione analogue **28j**, the oxidized form of **28g** and **28h**, demonstrated improved potency in both the biochemical and cellular assays (IC₅₀^{FP} = 0.11 μ M; IC₅₀^{Her2} = 0.034 μ M; IC₅₀^{HCT116} = 0.27) while losing all activity against NCI-ADR-RES (IC₅₀^{NCI-ADR-RES} = 100 μ M) and inheriting a poor metabolic profile.

The SAR was extended to amine containing analogues **28k**– **o**. In general, these analogues exhibited decreased potency in cell-based assays. In particular, the marked loss of potency in the NCI-ADR-RES cell line was observed regardless of substitution on the amino group. Tertiary dimethylamino analogue **28n** (IC₅₀^{NCI-ADR-RES} \geq 100 μ M) and sterically hindered proline analogue **28o** (IC₅₀^{NCI-ADR-RES} = 34 μ M) did not improve the cellular activity, suggesting both low cellular permeability and P-gp substrate susceptibility.

From the SAR studies described above, it was determined that modifications to the N9 piperidine substituent can significantly modulate both the potency and metabolic stability of these purine analogues and we concluded that the *N*-hydroxyacyl moieties present in analogues **28f**-h represented the optimal piperidine N-substituents, imparting the best balance between potency and metabolic stability.

The potential binding mode of these analogues has been examined by molecular modeling methods, and the best docking poses for all active compounds share common features. For example, from molecular modeling with **28g** and the Hsp90 N-terminal, ATP-binding domain reveals an interaction between the N9 piperidine ring and Ile110 side chain. In addition, H-bond donor–acceptor interactions between the lactamide carbonyl and Lys58 ε -amino group and between the lactamide hydroxyl and the Gly97 backbone carbonyl are key ligand–protein interactions (Figure 4).

By employment of N9-optimized analogues **28f**-**h** and initial lead **28a**, alternatives to the 6-bromo-1,3-benzodioxole moiety were explored next. The binding mode and preference for an *s*-*trans* conformation for this aryl moiety within the N-terminal ATP-binding pocket of Hsp90 are well documented.⁵⁸ As shown in Figure 4, our modeling with **28g** reveals a similar predisposition of the 6-bromo-1,3-benzodioxole moiety and, in addition to the conformational biasing imposed by the ligand bromine atom, points to a π - π interaction and edge-to-edge





Figure 4. Putative binding mode of 28g in the ATP-binding site of Hsp90 as determined by molecular modeling with Hsp90 crystal structure (PDB code 1UYI). Protein, ligand, and structured water molecules are rendered with Accelrys DS Visualizer 3.1. Atoms are colored by element: oxygen, red; nitrogen, blue; sulfur, green; ligand carbon, white; protein carbon, gold.

interaction with Phe138 and Trp162 and to a van der Waals interaction with the L107 isobutyl group as being major contributors to favorable binding energetics. Although a great deal of exploratory work has been performed in this region, these studies either were directed at a better understanding of the substituent effects at different positions of the 8-aryl group or were directed at replacement of the 8-aryl group with a benzothiazole ring.^{33,34,43,59} On the basis of the information from the literature, we carried out further SAR studies on this region by employing congeners of the 6-bromo-1,3-benzodioxole moiety, including bioisosteres, in order to gain insight into the structural features required for optimal potency and physical properties (Table 3).^{60–62}

First, a series of dihydrobenzofuran and benzofuran analogues was compared. 5-Bromo-2,3-dihydrobenzofuran 34a $(IC_{50}^{FP} = 0.04 \ \mu M)$ proved to be ~10 times more potent than 6-bromo-2,3-dihydrobenzofuran 34c ($IC_{50}^{FP} = 0.4 \mu M$) in the FP assay. The results of the Her2 assay (0.01 μ M, 34a, and 0.28 μ M, 34c) and antiproliferative activities on HCT116 cells (0.09 μ M, 34a, and 1.2 μ M, 34c) were consistent with the FP results and supported an on-target mechanism of cytotoxicity. The 5bromo-2,3-dihydroindole 34b, (S)-2-methyl-N-hyroxyacylpiperidine at N9, demonstrated potency similar to that of 34a. A similar trend was observed with benzofurans 34d and 34e, where 34d was >10-fold more potent than its regioisomer 34e in all four assays. Replacing both oxygen atoms in the benzodioxole ring with CH₂ provided indane 34f which was found to be very potent with IC₅₀ of 0.02 μ M in both the FP and HCT116 antiproliferative assays. It was encouraging that the non-benzodioxole analogues 34a,b, 34d, and 34f demonstrated comparable to improved activity relative to the corresponding 1,3-benzodioxole analogues. Noteworthy observations from this segment of the developing SAR were the following: (1) the benzodioxole oxygen atoms were not essential for binding affinity (cf., 28a vs 34f); (2) the effects of the oxygen atoms at the 1- or 3-position of the benzodioxole ring were not equal. The oxygen atom at the 3-position (para to the sulfur atom) was detrimental to potency, where in contrast the oxygen atom at the 1-position (meta to the sulfur atom) was tolerated (34a vs 34c; 34d vs 34e). While additional studies are needed to better understand this phenomenon, it appears that binding affinity is influenced by both conformational preferences and ring system electronic properties; see, for example, difluororo-1,3-benzodioxole analogue 34n which lost binding affinity (IC₅₀^{FP} > 5 μ M). Interestingly and contrary to our expectations, the metabolic stability of 34n was found to be very low (HLM = 0%). Since fluorine substitution at the methylene bridge of 1,3-benzodioxole ring systems can prevent oxidative metabolism,⁶³ difluoro-1,3-benzodioxole analogue 34n was expected to be metabolically stable.⁶⁴ Although metabolite identification is needed to identify the origins of instability, it is tempting to speculate that the increased lipophilicity of 34n (log P = 3.32, 3.42, 4.82, for 28g, 28a, 34n, respectively) is a contributing factor.

To further explore the effects of ring size, benzodioxanes 34g-j were compared to the corresponding benzodioxoles 28a and 28f-h. In general, benzodioxanes 34g-j had potency similar to that of the corresponding benzodioxoles in the FP assay but were slightly less potent in cell-based assays. Isomeric benzoxazines 34k and 34l demonstrated similar SAR trends, as evidenced by dihydrobenzofuran and benzofuran analogues 34a-e. Thus, benzoxazine 34k, with the oxygen atom meta to the sulfur atom, was 4- to 6-fold more potent than its isomer

Table 3



				^b HL			
Cmpd	R ₂	Ar	FP ^a	FP ^a Her2 ^a HCT11		NCI-ADR- RES ^a	M
34a	Н	60.01	0.04	0.01	0.09	1.80	nd
34b	∽он	Br 5	0.034	0.028	0.21	11	21
34c	Н	Br 6 O1	0.4	0.28	1.2	86	5
34d	Н	Br	0.059	0.048	0.26	1.1	53
34e	Н	Br	0.9	0.66	4.4	7.9	51
34f	Н	Br	0.02	nd	0.02	0.23	1
34g	Н		0.06	0.049	0.67	2.1	42
34h	CH ₂ OH	,	0.09	0.04	0.82	10	45
34i	Г∕үон	Br	0.15	0.074	0.47	6.5	45
34j	Кон	5	0.11	0.069	0.92	9.8	35
34k	Н	Br	0.065	0.032	0.25	100	nd ^c
341	Н		0.31	0.21	1.5	20	0
34m	н	Br	0.06	0.06	0.27	100	30
34n	н	Br OFF	5	nd	nd	nd	0
340	Н	hao	0.21	0.092	1.4	7.6	31
34p	∽он		0.65	0.54	2.7	20	32
34q	Н	NC O	0.21	0.25	25	nd	81

^{*a*}Average of at least two experiments. Assay error for FP is $\pm 10\%$ and $\pm 30\%$ for remaining assays. ^{*b*}Metabolic stability in human liver microsomes; percent parent remaining after 40 min of incubation. ^{*c*}Not determined.

341 (IC₅₀^{FP} = 0.065 and 0.31 μ M for 34k and 341; IC₅₀^{HCT116} = 0.25 and 1.5 μ M for 34k and 341). Indanone 34m, a nonclassical bioisostere of benzodioxole 28a,⁶¹ exhibited good potency in the FP (IC₅₀^{FP} = 0.06 μ M) and cytotoxicity assays (IC₅₀^{Her2} = 0.06 μ M; IC₅₀^{HCT116} = 0.27 μ M). The nonbenzodioxole analogues were subsequently evaluated for metabolic stability. Inhibitors 34a–c and 34f, bearing benzylic methylene protons, and benzoxazines 34k,l exhibited rapid metabolism upon incubation in human microsomes, and

Table 4. Pharmacokinetic Parameters of 28a, 28f-h, and 34d,g-j in Mice

	iv (2.5 mg/kg) ^{<i>a</i>}				po (10 mg/kg) ^b			
compd	$(mL \stackrel{CL}{h^{-1}} kg^{-1})$	V (mL/kg)	$egin{array}{c} t_{1/2} \ ({ m h}) \end{array}$	AUC (h∙ng/mL)	C _{max} (ng/mL)	$\begin{array}{c} T_{\max} \\ (\mathrm{h}) \end{array}$	AUC (h∙ng/mL)	F (%)
28a	1899	1452	0.5	1316	354	1.0	1808	35
28f	4359	3005	0.5	574	588	0.25	1318	57
28g	1187	2438	1.4	2106	2802	0.25	3214	38
28h	1513	1321	0.6	1653	1429	0.25	2410	37
34g	2585	1053	0.28	967	312	1.0	1175	30
34h	4833	5927	0.85	517	55	0.25	702	34
34i	1712	1070	0.43	1460	564	0.5	1193	20
34j	1639	1347	0.6	1526	1183	1	1960	32
34d	2841	1058	0.3	880	2231	0.5	4612	131
^a Formulation: DMA/PEG300/EtOH/H ₂ O (3/40/12/45, v/v/v/v). ^b Formulation: DMA/PEG300 (5/95, v/v).								

benzodioxanes 34g–j, benzofurans 34d,e, and indanone 34m displayed stability similar to that of benzodioxoles 28a and 28f-h. On the basis of their equivalent potency and metabolic stability to 28a and 28f–h, benzodioxanes 34g–j and benzofuran 34d were advanced into PK evaluations. Indanone 34m was excluded from PK analyses because of lack of potency in NCI-ADR-RES (IC₅₀^{NCI-ADR-RES} \geq 100 μ M).

Analogues **340–q**, where the 1,3-benzodioxole ring bromine atom was replaced with a chloro or cyano, were also examined. Not surprisingly and in accord with previous studies, replacement of Br with Cl led to a ~2-fold decrease in potency.^{43,58} Although cyano derivative **34q** showed significantly enhanced metabolic stability (HLM = 81%), the cellular potency dropped unacceptably by 4- to 46-fold (IC₅₀^{Her2} = 0.25 μ M; IC₅₀^{HerT116} = 25 μ M).

Ultimately, nine inhibitors, **28a**, **28f-h**, and **34d**,**g-j** were selected for intravenous (2.5 mg/kg) and oral (10 mg/kg) PK evaluations in Swiss nude mice (Table 4).

Several interesting observations were made as result of these initial PK evaluations. First, 1,3-benzodioxole analogues 28a and 28f-h demonstrated favorable PK profiles in comparison to the corresponding 1,4-benzodioxanes 34g-j (28a vs 34g; 28f vs 34h; 28g vs 34i; 28h vs 34j). Second, compounds 28f and 34h, possessing N-hydroxyacetyl substituents on the piperidine nitrogen, suffered from high hepatic clearance $(>4300 \text{ mL } \text{h}^{-1} \text{ kg}^{-1})^{65}$ and concomitantly low exposure. Third, inhibitor 28g displayed superior oral PK profiles with a high C_{max} (2802 ng/mL, ~5.1 μ M), good overall exposure $(3214 \text{ h} \cdot \text{ng/mL})$, and a reasonable hepatic clearance rate. Fourth, most compounds showed rapid absorption following oral administration in mice $(T_{\text{max}} = 0.25-1 \text{ h})$. Finally, the quantitative oral bioavailability (F > 100%) of benzofuran 34d was entirely unexpected given the structural similarity of these purine analogues. Oral bioavailability values of >100% have been reported in literature, and the phenomenon has several contributing factors.⁶⁶ Regardless of mechanism, the uncharacteristic PK behavior for 34d led us to eliminate it from further study. For purposes of triaging compounds into human tumor xenograft studies, the mouse PK (100 mg/kg, oral, Table 5) of the eight remaining compounds was evaluated. In the PK study for these analogues, less than expected increases in AUC and C_{max} were observed in general. This effect is possibly due to the dissolution rate or solubility-limited absorption. Most of these analogues belong to BCS (biopharmaceutics classification system) class II. For example, 28g is modestly soluble (~20 μ M at pH 7.4 in phosphate buffer) but highly permeable (>350 $x10^{-6}$ cm/s, PAMPA assay). Issues relating to the solubility and

Table 5. Pharmacokinetic Parameters of 28a, 28f-h, and 34g-j (po, 100 mg/kg)^{*a*}

compd	C _{max} (ng/mL)	AUC (h·ng/mL)	Hsp70 induction ^b
28a	10940	63900	47
28f	7780	25100	18
28g	13100	81800	53
28h	8400	50300	24
34g	8540	38000	2.3
34h	7530	18200	1.7
34i	11600	40400	3.2
34j	9300	32600	3.8
^{<i>a</i>} Formulati	on: 40% Captisol	in phosphate buffer.	^b Fold over control.

absorption properties of drug candidates are frequently encountered during the drug discovery process, and this compound class could be addressed by formulation.⁶⁷ In this instance, formulation in a Captisol (modified cyclodextrin) and phosphate buffer system enhanced oral bioavailability dramatically (e.g., F > 50%, for **28a,f-h** and **34g-j**).

In these PK studies, HSP70 mRNA induction in liver at 6 h after treatment was also measured. HSP70 is robustly upregulated in response to Hsp90 inhibition and is a validated pharmacodynamics biomarker. Induction of HSP70 indicates that the drug is both reaching the intended target site and exerting pharmacological effects via the Hsp90 mechanism. Although the effects of Hsp90 inhibitors on HSP70 induction are expected to be different in tumors and normal cells or tissues,^{68,69} this experiment would provide early evidence of target modulation in vivo.

In accord with the previous PK studies (Table 4), **28g** showed the best PK profile with a C_{max} of 13100 ng/mL (~23 μ M) and an AUC of 81 800 h·ng/mL with excellent oral bioavailability (97%). The C_{max} was 20- to 60-fold higher than IC₅₀ values in representative cancer lines in vitro (Table 6). Initial lead compound **28a** also exhibited a profile fairly similar

Table 6. Antiproliferative Activity for 28g

cell line	$IC_{50} (\mu M)^a$	cell line	$IC_{50} (\mu M)^a$
HT-29 (colon)	0.42	A549 (NSCLC)	0.77
HCT-116 (colon)	0.54	OVCAR8 (ovarian)	0.49
LNCaP (prostate)	0.51	NCI-N87 (gastric)	0.20
DU-145 (prostate)	0.53	BT-474 (breast)	0.55
NCI-H69 (SCLC)	0.15	MV4–11 (leukemia)	0.25

^{*a*}Average of two or more experiments; standard deviation was $\pm 30\%$.

to that of **28g**. Benzodioxane analogues **34g**-j had inferior AUC and C_{max} values relative to the corresponding 1,3benzodioxaole analogues. Interestingly, only 2- to 4-fold induction of liver HSP70 levels was observed for benzodioxane analogues **34g**-j whereas an 18- to 53-fold induction was achieved with 1,3-benzodioxoles **28a** and **28f-h**. This phenomenon may reflect differences in cellular potency or PK properties. However, the similarities in potency and PK of benzodioxole **28f** and benzodioxazines **34g**-j, the former showing 5- to 10-fold higher HSP70 induction than the latter, suggest that other factors are likely in play. Both the PK and HSP70 induction profiles made analogue **28g** the most promising candidate for further development.

With benzodioxole **28g** demonstrating optimal PK properties, its antiproliferative activity against an array of cancer cell lines was profiled and revealed broad spectrum activity with IC_{50} values ranging from 0.1 to 0.8 μ M (Table 6). In order to confirm the cellular mode of action of **28g**, HCT-116, NCI-N87, and DU-145 cells were exposed to varying concentrations of **28g** for 24 h and the cell lysates were probed with antibodies to Her2, Akt, and Hsp70. As anticipated, Western blot analysis of **28g** in NCI-N87, HCT-116, and DU-145 cell lysates revealed dose-dependent client protein degradation (Akt and Her2) and Hsp70 induction (Figure 5). Importantly, the IC₅₀




Figure 5. Effect of 28g on Hsp90 client protein (Her2, Hsp70, and Akt) expression in NCI-N87, HCT116, and DU-145 cell lines by Western blot analyses. Cells were exposed to varying concentrations of 28g for 24 h, and then cell lysates were probed with Her2-, Hsp70-, and Akt-specific antibodies.

values for client protein degradation $(0.1-0.5 \ \mu M)$ were commensurate with cellular cytotoxicity, suggesting a direct relationship between biomarker response and drug exposure. The change in client protein and biomarker levels observed in cells exposed to **28g** provided evidence that the observed cellular cytotoxicity was a result of Hsp90 inhibition.

On the basis of its favorable in vitro profiles and PK properties, **28g** was evaluated in a human xenograft study in mice (Figure 6). In the NCI-N87 gastric cancer xenograft model, **28g** was administered orally for 22 days at doses of 50, 75, 125, or 200 mg/kg and demonstrated dose-related inhibition of tumor growth. The 50 and 75 mg/kg doses resulted in tumor growth inhibition (p < 0.01) of 37% and 62%, respectively, and the 125 and 200 mg/kg doses resulted in tumor regression (p < 0.0001) of 10% and 48%, respectively. Both the dose level and schedule were well tolerated as

evidenced by lack of significant weight loss. Furthermore, robust HSP70 induction in liver and tumor tissue supports ontarget, Hsp90-mediated antitumor effects by **28g** in NCI-N87 tumor-bearing mice (Figure 6b).

CONCLUSION

An extensive SAR study aimed at enhancing potency and druglike properties of lead Hsp90 inhibitor 28a was executed. During the course of these studies, new and improved synthetic methods for C–S bond formation were developed that enabled rapid generation of potential inhibitors and dramatically broadened the scope of the SAR. Through a combination of modifications to the pendent purine N-9 piperidine moiety and congeneric series of 1,3-benzodioxole ring at C8, several potent Hsp90 inhibitors were identified. Pharmacokinetic analyses led to selection of 28g as the most promising drug candidate. Following oral administration of 28g to mice (100 mg/kg), the plasma C_{max} (~23 μ M) was 20- to 60-fold higher than its IC₅₀ values for cancer cell lines in vitro and with good systemic exposure (AUC = $81\,800\,h\cdot ng/mL$). Importantly, inhibitor 28g showed significant antitumor effects in a human cancer xenograft model with concomitant and robust Hsp70 mRNA induction, a pharmacodynamic marker of Hsp90 inhibition.

Compound **28g** (MPC-3100) has completed a phase I clinical evaluation in refractory, or recurrent, cancer patients. This clinical study demonstrated that **28g** was safe and tolerated when administered at doses below 600 mg per day with the most common side effects being of gastrointestinal origin, including diarrhea, nausea, and vomiting.⁷⁰ The results of further clinical evaluation will be reported in due course.

EXPERIMENTAL SECTION

Biology. Binding Assay. Compound binding to purified Hsp90 was monitored using BODIPY-labeled geldanamycin (BODIPY-GM) in a fluorescence polarization assay adapted from the literature method.⁷¹ Compound dilutions (in 100% DMSO) were added to black-bottom 96-well plates (Greiner, 2% DMSO final), and equal volumes of BODIPY-GM (10 nM final) and purified human Hsp90 (Stressgen, SPP-770; 30 nM final) in assay buffer (20 mM HEPES-KOH, pH 7.3, 50 mM KCl, 5 mM MgCl₂, 20 mM Na₂MoO₄, 0.01% NP-40, 0.1 mg/mL bovine γ-globulin [Invitrogen, P2045], 2 mM DTT) were added sequentially to yield a final volume of 50 μ L. Plates were incubated overnight at room temperature. Parallel and perpendicular fluorescence measurements were read (LJL BioSystems Analyst AD plate reader) with excitation and emission wavelengths of 485 and 530 nm, respectively. Background fluorescence (buffer only) was subtracted, and fluorescence polarization (FP) values, expressed in mP units, were calculated from parallel and perpendicular fluorescence readings as follows: FP = [(parallel - perpendicular)/(parallel + perpendicular)] × 1000. Percent inhibition was calculated by normalizing the FP values to those obtained in parallel reactions containing DMSO and subtracting these normalized values from 100%. Intrinsic compound fluorescence was independently monitored, and FP data points confounded by compound fluorescence were excluded from the analysis.

Her2-Luciferase Degradation Assay. The Her2-luciferase construct was constructed by joining sequences encoding the kinase domain (aa 641–975) of Her2 to those encoding firefly luciferase.^{72,73} HCT116 cells stably transfected with the Her2 (kinase domain)-luciferase fusion were seeded into black 96-well plates at 10 000 cells per well in 100 μ L (DMEM supplemented with 10% serum) and incubated overnight. Compound dilutions (in 100% DMSO) were added to individual wells (0.4% DMSO final), and plates were incubated for 4 h. Plates were equilibrated to room temperature (5 min), 100 μ L of Steady-Glo reagent (Promega no. E2520) was added




Figure 6. (a) In vivo efficacy data for **28g** (50, 75, 125, or 200 mg/kg, q.d., po 22 days) in the NCI-N87, Her2⁺ human gastric cancer xenograft model. (b) Change in HSP70 expression level in NCI-N87 tumor-bearing mice. Mice with NCI-N87 tumors (median volume, ~425 mm³) were given a single oral dose of **28g** (200 mg/kg). Blood, tumor, and liver samples (n = 6) were collected at 0.25, 0.5, 1, 2, 4, 8, 12, 36, and 48 h after dose for determination of compound concentrations in plasma and Hsp70 RNA levels in tumor and liver.

per well, and plates were incubated at room temperature for 5 min. Luminescence was then measured (TopCount, Perkin-Elmer).

Cytotoxicity Assay. Cells were seeded into black 96-well plates at 5000 cells per well in 100 μ L (DMEM supplemented with 10% serum) and incubated overnight. Compound dilutions (in 100% DMSO) were added to individual wells (0.4% DMSO final), and plates were incubated for 72 h. Plates were equilibrated to room temperature (5 min). An amount of 50 μ L of lysis buffer followed by 50 μ L of substrate solution (ATPLite [two-step], Perkin-Elmer, no. 601941) was added to each well, and plates were incubated at room temperature for 5 min. Luminescence was then measured (TopCount, Perkin-Elmer).

Microsomal Stability Assays. Metabolic stability of the test article was assessed in liver microsomes from multiple species (e.g., mouse, rat, dog, monkey, or human) with and without NADPH. Concentrations of test article were determined by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. The test article was incubated in duplicate in the presence of microsomes diluted to 0.5 mg/mL of total protein in 100 mM potassium phosphate buffer (pH 7.4). NADPH-dependent metabolism was initiated with the addition of 1 mM NADPH. Aliquots of sample were removed at 0, 10, 20, and 40 min after NADPH addition, and the reaction was stopped by addition of acetonitrile. Following centrifugation, supernatants were dried under a stream of nitrogen and reconstituted in an appropriate solvent. Samples were quantified by determining peak area from LC-MS/MS analysis. Typically, analytes were ionized by positive-ion electrospray ionization and detected by multiple-reaction monitoring on an ABI Q-Trap mass spectrometer. Peak areas of the duplicates at the various time points were integrated, and the percent of compound remaining at 10, 20, and 40 min was compared to the peak area at 0 min. "No NADPH" control samples were incubated for 40 min and analyzed in the same manner.

PAMPA Permeability Assay. Permeability of a test compound was determined using the double-sink parallel artificial membrane permeability analysis (PAMPA) method (pION Inc.). Donor solutions were prepared at three pH levels of 5.0, 6.2, and 7.4. pION'S ASB 7.4

buffer was placed in the permeation plate, and the filter plate was painted with a phospholipid mixture dissolved in dodecane. Test compounds were then added to the filter plate, which was then placed on top of the permeation plate to form the PAMPA sandwich. The sandwich was incubated for 30 min at 37 °C with a mixing speed equivalent to an aqueous boundary layer of 40 μ m. Spectra were collected from 250 to 490 nm (Spectra-Max, Molecular Devices). Permeability was calculated from the spectra using pION's software. Verapamil was analyzed at the same time and served as positive control.

Pharamacokinetic Studies. All pharmacokinetic studies of test articles were conducted in mice. Plasma and tissue concentrations of the test article were quantified by LC-ESI-MS/MS using an internal standard and calibration curve with quality control samples. Animals were dosed intravenously or orally. The basic pharmacokinetics of the test article was determined in female CD-1 or Nu[±] mice dosed at 2.5 mg/kg intravenously. The dosing vehicle consisted of DMA/PEG300 (N,N-dimethylacetamide, polyethylene glycol 300, ethanol, and water in a ratio of 3/40/12/45, respectively). Three or five animals were used per time point, and the time points collected were 5, 15, 30, 60, 120, 240, 480, and 720 minutes after administration. Blood samples were collected through cardiac puncture, and plasma was obtained with EDTA as the anticoagulant. Plasma was submitted for bioanalysis (described below). For oral dosing, the test article was administered via oral gavage formulated in one of the following: DMA/PEG300 (N,N-dimethylacetamide and polyethylene glycol 300 in a ratio of 5/ 95 or 10/90), CMC/Tween 80 (2% carboxymethylcellulose, low viscosity with 0.05% Tween 80 in HPLC grade water), or 40% Captisol in phosphate. Concentrations of the test article were determined by adding 10 μ L of internal standard to 50 μ L of sample and then precipitating protein with 1 mL of acetonitrile. The supernatant was injected onto a reverse-phase HPLC column. Separation was achieved by gradient elution. Analytes were ionized by positive-ion electrospray ionization and detected by multiplereaction monitoring on an ABI Q-Trap. Peak area ratios of the test article and internal standard were compared to those from a multipoint standard curve spanning a range from 10 to 10 000 ng/mL. To

confirm accuracy, quality control samples were analyzed in duplicate at four different concentrations. Bioanalytical run acceptance required that at least three-fourths of the calibration standards were within 15% of theoretical and that greater than $^2/_3$ of all quality control samples were within 25% of theoretical. Plasma concentration data were fit with WinNonLin using noncompartmental analysis.

In Vivo Xenograft Study (NCI-N87 Xenograft). Five million NCI-N87 cells were implanted subcutaneously in the right flank of female nude mice (Crl:NU-Fox1nu). When the median tumor volume was approximately >100 mm³, mice were randomized into 5 cohorts of 10 animals each. Cohort 1 was dosed once daily with vehicle (40% w/ w Captisol), cohort 2 with 200 mg/kg, 28g once daily, cohort 3 with 125 mg/kg, 28g once daily, cohort 4 with 75 mg/kg, 28g once daily, and cohort 5 with 50 mg/kg, 28g once daily. All cohorts were dosed for 22 days. Tumor measurements and body weight determinations were performed a minimum of 2 times weekly.

Chemistry. All solvents and reagents were purchased from commercial sources and used without further purification unless otherwise noted. Reactions were monitored by TLC (thin layer chromatography) using 0.25 mm silica gel 60 F254 plates purchased from EMD chemicals or LC-MS (ESI) using an Agilent 1100 series LC/MSD ion-trap instrument with an Xterra MS C18 (Waters) 4.6 mm \times 50 mm, 5 μ m column. Purification was performed with either ISCO CombiFlash (Foxy Jr. fraction collector, UA-6 detector) or a reverse phase HPLC (RP-HPLC) on an Agilent 1100 Prep-LC with various columns. ¹H NMR spectra were recorded on a Bruker Mercury 400 MHz instrument. Proton chemical shifts are expressed in parts per million (ppm) relative to TMS and calibrated using residual undeuterated solvent as internal reference. High-resolution mass spectra (HRMS) were recorded on an Agilent 6210 TOF LC-MS instrument using electronspray ionization (ESI). GC-MS analysis was performed on an Agilent Technology 6890N. Determination of the enantiomeric purity of chiral compounds was performed on a Chiralcel OJ-RH column, using 100% MeOH with 0.01% TEA (isocratic, 0.5 mL/min). Compound purity was determined by an Agilent HP1100 instrument with a 4.6 mm \times 150 mm Xterra C18 3.5 μ m column. The flow rate was 1.2 mL/min, and the injection volume was 5 μ L. HPLC conditions were as follows: mobile phase A, HPLC grade water (0.01% TFA); mobile phase B, HPLC grade acetonitrile (0.01% TFA); UV detector, 203 and 280 nm; gradient, 95% A/5% B to 0% A/100% B in 10 min, 100% B in 10-11 min, 100% B to 95% A/5% B in 11-13 min, 95% A/5% B in 13−15 min. All final compounds were ≥95% pure by HPLC at both 203 and 280 nm unless otherwise stated.

Intermediates **24a**–**c**,**f**,**g**, **25a**, **29**, **30a**,**b**, **41**, **42**, **47**, and **50** were purchased from commercial vendors, and **24d**,**e** were prepared by adapting literature procedures (in Supporting Information). The log *P* value was calculated using Chemdraw software.

8-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-6amine (26a).³³ To a 250 mL round-bottomed flask was added 8mercaptoadenine (21) (2.00 g, 12.0 mmol), 5,6-dibromobenzo[1,3]dioxole (24a) (6.70 g, 24.0 mmol), Pd₂dba₃ (0.548 g, 0.599 mmol), xantphos (0.693 g, 1.20 mmol), K₂CO₃ (3.31 g, 24.0 mmol), and dry, degassed dioxane (25 mL). The mixture was heated at 100 °C for 16 h under nitrogen, cooled to room temperature, filtered, and washed with a mixture of CH₂Cl₂, EtOAc, and MeOH (2/2/0.5 (v/v/v)). The combined filtrates were concentrated in vacuo. The dark brown residue was purified by chromatography on SiO₂ (CH₂Cl₂/EtOAc/ MeOH, 2/2/0.5), and subsequent recrystallization from MeOH provided 26a (1.4 g, 32%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.08 (s, 1H), 7.38 (s, 1H), 7.23 (s, 1H), 6.12 (s, 2H); LC–MS [M + H⁺] 365.9; HPLC purity, 94.2% (*t*_R = 4.20 min).

5-[(6-Amino-9*H***-purin-8-yl)thio]-6-bromoindan-1-one (26f).** The title compound was prepared in 24% yield from **21** and **24f** in a manner similar to that described for **26a**. ¹H NMR (400 MHz, DMSO- d_6) δ 8.17 (s, 1H), 7.87 (s, 1H), 7.58–7.44 (brs, 2H), 7.14 (s, 1H), 2.95–2.91 (m, 2H), 2.63–2.60 (m, 2H); HRMS (ESI-TOF) calcd for C₁₄H₁₀BrN₅OS [M + H⁺] 375.9862, found 375.9857.

6-[(6-Amino-9H-purin-8-yl)thio]-1,3-benzodioxole-5-carbonitrile (26g). The title compound was prepared in 15% yield from 21 and 24g in a manner similar to that described for 26a. ¹H NMR (400 MHz, DMSO- d_6) δ 8.08 (s, 1H), 7.59 (s, 1H), 7.29 (s, 1H), 7.26–7.16 (brs, 2H), 6.23 (s, 2H); HRMS (ESI-TOF) calcd for C₁₃H₈N₆O₂S [M + H⁺] 313.0502, found 313.0509.

tert-Butyl 4-{2-[(Methylsulfonyl)oxy]ethyl}piperidine-1-carboxylate (25a). To a solution of 30a (15.0 g, 65.4 mmol) in CH_2Cl_2 (100 mL) were added MsCl (11.0 mL, 131 mmol) and NEt₃ (23 mL, 164.0 mmol) at ~5 °C, and the mixture was stirred at room temperature for ~16 h. Upon completion, the mixtue was diluted with CH_2Cl_2 (100 mL) and washed with water (100 mL × 2), dried (Na₂SO₄), filtered, and concentrated in vacuo to provide 25a (20.0 g) in quantitative yield. LC-MS [M + H⁺] 347.1.

2-(1-Formyl-4-piperidyl)ethyl 4-Methylbenzenesulfonate (25b). To a solution of 30b (3.00 g, 19.1 mmol) in CH_2Cl_2 (50 mL) were added NEt₃ (8.00 mL, 57.3 mmol) and DMAP (23 mg, 0.19 mmol), followed by TsCl (3.64 g, 19.1 mmol). After being stirred for 10 h at room temperature, the mixture was diluted with CH_2Cl_2 , washed with brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. Purification of the residue by column chromatography (SiO₂, EtOAc/hexane, 50–100%) provided 25b (2.22 g, 37%). LC–MS [M + H⁺] 311.9.

2-{1-(1-Methyl-1*H*-tetrazol-5-yl)piperidin-4-yl}ethyl 4-Methylbenzenesulfonate (25h). To a solution of 29 (864 mg, 6.70 mmol) in CH₂Cl₂ (22 mL) was added methyl isothiocyanate (490 µL, 6.70 mmol). After being stirred for 10 h at room temperature, the mixture was concentrated in vacuo and the residue was purified by SiO₂ column chromatography (EtOAc) to provide 31a (1.04 g, 77%). To a mixture of **31a** (1.63 g, 8.07 mmol), HgCl₂ (2.41 g, 8.88 mmol), and NaN3 (1.57 g, 24.2 mmol) in DMF (20 mL) was added NEt3 (3.37 mL, 24.2 mmol). After being stirred for 10 h at room temperature, the reaction mixture was filtered and the filter cake was washed with CH2Cl2. The combined filtrates and washings were washed with brine, dried (Na₂SO₄), filtered, concentrated in vacuo, and the residue purified by SiO2 chromatography (60% EtOAc in hexane) to afford 2-{1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl}ethanol (0.720 g, 42%). LC-MS [M + Na⁺] 234.0. 25h (0.417 g, 80%) was obtained from 2-{1-(1-methyl-1H-tetrazol-5-yl)piperidin-4yl}ethanol (0.399 g, 1.42 mmol) in a manner similar to that described for 25a. HRMS (ESI-TOF) calcd for C16H23N5O3S [M + H⁺] 366.1594, found 366.1593.

4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carbaldehyde (28a). To a solution of 26a (1.00 g, 2.73 mmol) and tosylate 25b (1.02 g, 3.28 mmol) in DMF (6.8 mL) was added Barton's base (677 μ L, 3.28 mmol). After being stirred at 80 °C for 10 h, the mixture was cooled to room temperature and diluted with EtOAc and water. The precipitate was filtered, washed with water and EtOAc, and dried to yield 28a (400 mg, 29%). The combined filtrates were concentrated in vacuo, and the residue was purified by preparative RP-HPLC to afford additional 28a (151 mg) and N3 regisomer (281 mg). ¹H NMR (400 MHz, DMSO d_6) δ 8.16 (s, 1H), 7.94 (s, 1H), 7.46–7.41 (brs, 2H), 7.39 (s, 1H), 6.81 (s, 1H), 6.09 (s, 2H), 4.18 (t, J = 7.2 Hz, 1H), 4.10 (brd, J = 13.2 Hz, 1H), 3.62 (brd, J = 12.8 Hz, 1H), 2.95 (td, J = 12.4, 2.8 Hz, 1H), 2.44 (m, 1H), 1.78–1.67 (m, 2H), 1.61 (q, J = 7.2 Hz, 2H), 1.44 (m, 1H), 1.01 (m, 1H), 0.91 (m, 1H); HRMS (ESI-TOF) calcd for $C_{20}H_{21}BrN_6O_3S [M + H^+]$ 505.0652, found 505.0662; HPLC purity, 96.7% ($t_{\rm R} = 7.32$ min).

8-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(1-isopropyl-4-piperidyl)ethyl]purin-6-amine (27c). The title compound was prepared from **26a** and **25c** in a manner smilar to that described for **28a**. ¹H NMR (400 MHz, CD₃OD) δ 8.23 (s, 1H), 7.27 (s,1H), 7.13 (s, 1H), 6.08 (s, 2H), 4.38–4.30 (m, 2H), 3.62–3.52 (m, 2H), 3.36– 3.26 (m, 1H), 3.05–2.98 (m, 2H), 2.96–2.84 (m, 2H), 1.80–0.80 (m, 11H); LC–MS [M + H⁺] 519.1; HPLC purity, 99.9% ($t_{\rm R}$ = 6.10 min).

8-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(1-isobutyl-4-piperidyl)ethyl]purin-6-amine (27d). The title compound was prepared from **26a** and **25d** in a manner smilar to that described for **28a**. ¹H NMR (400 MHz, CD₃OD) δ 8.22 (s, 1H), 7.30 (s, 1H), 7.10 (s, 1H), 6.10 (s, 2H), 4.40 (t, J = 7.2 Hz, 2H), 3.60–3.58 (m, 2H), 3.00–2.90 (m, 2H), 2.15–2.10 (m, 2H), 2.00–1.90 (m, 2H), 1.90–

1.80 (m, 2H), 1.60–1.50 (m, 2H), 1.30–1.20 (m, 2H), 1.10–1.00 (m, 6H); LC–MS [M + H⁺] 533.1; HPLC purity, 99.9% ($t_{\rm R}$ = 6.31 min).

8-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-[1-(2,2,2-tri-fluoroethyl)-4-piperidyl]ethyl]purin-6-amine (27e). The title compound was prepared from **26a** and **25e** in a manner similar to that described for **28a**. ¹H NMR (400 MHz, CD₃OD) δ 8.29 (s, 1H), 7.28 (s, 1H), 7.18 (s, 1H), 6.09 (s, 2H), 4.35 (t, *J* = 7.2 Hz, 2H), 3.56–3.50 (m, 2H), 3.35 (s, 2H), 3.30–3.25 (m, 2H), 2.69–2.59 (m, 3H), 2.00–1.40 (m, 4H); LC–MS [M + H⁺] 559.0; HPLC purity, 97.0% ($t_{\rm R}$ = 7.16 min).

8-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-[1-(cyclo-hexylmethyl)-4-piperidyl]ethyl]purin-6-amine (27f). The title compound was prepared from **26a** and **25f** in a manner similar to that described for **28a**. ¹H NMR (400 MHz, CD₃OD) δ 8.20 (s, 1H), 7.10 (s, 1H), 6.08 (s, 2H), 4.35–4.30 (m, 2H), 3.60–3.53 (m, 2H), 2.93–2.84 (m, 4H), 2.16–0.80 (m, 18H); HPLC purity, 99.9% ($t_{\rm R}$ = 6.75 min).

8-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(1-prop-2ynyl-4-piperidyl)ethyl]purin-6-amine (27g). The title compound was prepared from 26a and 25g in a manner similar to that described for 28a. ¹H NMR (400 MHz, CD₃OD) δ 8.26 (s, 1H), 7.28 (s, 1H), 7.16 (s, 1H), 6.09 (s, 2H), 4.36 (t, J = 7.6 Hz, 2H), 4.10–4.02 (m, 2H), 3.68 (brd, J = 14.0 Hz, 2H), 3.02 (brt, J = 12.4 Hz, 2H), 2.66 (s, 1H), 2.21 (brd, J = 14.8 Hz, 2H), 1.90–1.81 (m, 2H), 1.62–1.60 (m, 1H), 1.56–1.44 (m, 2H); LC–MS [M + H⁺] 515.1; HPLC purity, 97.9% ($t_{\rm R} = 6.15$ min).

8-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-[1-(1-meth-yltetrazol-5-yl)-4-piperidyl]ethyl]purin-6-amine (27h). The title compound was prepared from **26a** and **25h** in a manner similar to that described for **28a**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.20 (s, 1H), 7.65–7.50 (brs, 2H), 7.40 (s, 1H), 6.85 (s, 1H), 6.10 (s, 2H), 4.22 (t, *J* = 7.6 Hz, 2H), 3.85 (s, 3H), 3.55 (brd, *J* = 12.8 Hz, 2H), 2.85 (t, *J* = 12.8 Hz, 2H), 1.78 (brd, *J* = 12.8 Hz, 2H), 1.70–1.62 (m, 2H), 1.43 (m, 1H), 1.35–1.22 (m, 2H); HRMS (ESI-TOF) calcd for C₂₁H₂₃BrN₁₀O₂S [M + H⁺] 559.0982, found 559.0974; HPLC purity, 95.1% (*t*_R = 7.56 min).

8-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-[1-(1-*tert***-butyltetrazol-5-yl)-4-piperidyl]ethyl]purin-6-amine (27i).** The title compound was prepared from **26a** and **25i** in a manner similar to that described for **28a**. ¹H NMR (400 MHz, CD₃OD) δ 8.21 (s, 1H), 7.27 (s, 1H), 7.10 (s, 1H), 6.08 (s, 2H), 4.35 (t, *J* = 7.6 Hz, 2H), 3.14 (brd, *J* = 12.4 Hz, 2H), 2.92 (t, *J* = 12.0 Hz, 2H), 1.92 (brd, *J* = 10.0 Hz, 2H), 1.83 (brq, *J* = 8.0 Hz, 2H), 1.73 (s, 9H), 1.58–1.42 (m, 3H); HRMS (ESI-TOF) calcd for $C_{24}H_{29}BrN_{10}O_2S$ [M + H⁺] 601.1452, found 601.1461; HPLC purity, 99.9% (t_R = 8.65 min).

tert-Butyl 4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carboxylate (27a). *Method A*. The title compound was prepared from 26a and 25a in a manner similar to that described for 28a. HRMS (ESI-TOF) calcd for $C_{24}H_{29}BrN_6O_4S$ [M + H⁺] 577.1227, found 577.1279; HPLC purity, 97.3% (t_R = 7.02 min).

Method B. The title compound was prepared from 33a and aryl sulfide 43a in a manner similar to that described for 34a.

Method C. To a solution of 33a (13.2 g, 31.1 mmol) and 1,3benzodioxol-5-thiol (58) (7.17 g, 46.6 mmol) in DMF (60 mL) was added K₂CO₃ (93.17 mmol, 12.87 g). After being stirred at 100 °C for 3-6 h, the mixture was cooled to room temperature, filtered, and washed with EtOAc. The combined filtrates were diluted with EtOAc (120 mL), washed with water (100 mL \times 2), brine (100 mL), dried (Na₂SO₄), filtered, and concentrated to 30 mL. The solid was precipitated by adding hexane (50 mL), filtered, and washed with a 1:2 (v/v) mixture of EtOAc/hexanes to afford the product (14.5 g, 94%). ¹H NMR (CDCl₃) δ 8.30 (s, 1H), 7.02 (dd, J = 7.8, 1.9 Hz, 1H), 6.96 (d, J = 1.9 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 5.99 (s, 2H), 4.23 (t, J = 7.4 Hz, 2H), 4.38-3.98 (m, 2H), 2.3-2.15 (m, 2H), 1.82-1.66 (m, 4H), 1.49–1.35 (m, 10H), 1.22–1.1 (m, 2H); LC–MS [M + H⁺] 499.1. A mixture of the above product (10.0 g, 20.0 mmol) in acetic acid (37 mL) was cooled to 10 °C and treated with NBS (4.28 g, 24.1 mmol) in portions. After the mixture was stirred for 1 h at room temperature, additional NBS (~ 2 g) was added. The mixture was

stirred for 4 h. Upon completion, the mixture was cooled to 15 $^{\circ}$ C, quenched with aqueous sodium bisulfate (prepared from 11 g of sodium metasulfite and 100 mL of water), stirred at room temperature overnight, filtered, washed with water, and air-dried to give the crude product. The crude was crystallized from methanol to afford **27a** (8.5 g, 73% yield).

8-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(4piperidyl)ethyl]purin-6-amine (27b). To a suspension of 27a (14.0 g, 0.025 mol) in CH₂Cl₂ (82 mL) was added TFA (27 mL, 0.37 mol) at 10 °C. After being stirred for 2 h at room temperature, the mixture was concentrated in vacuo and the residual TFA was removed by azeotropic distillation with AcCN. The remaining oil was dissolved in AcCN (11 mL), and the solution was added to a NH₄OH solution (29%, w/w, 71 mL) at 10 °C. The solid was filtered, washed with water, and air-dried (11.8 g, 99%). ¹H NMR (400 MHz, DMSO- d_6) δ 8.16 (s, 1H), 7.52–7.43 (brs, 2H), 7.39 (s, 1H), 6.81 (s, 1H), 6.09 (s, 2H), 4.18 (t, *J* = 7.0 Hz, 2H), 3.23 (d, *J* = 11.2 Hz, 2H), 3.16 (m, 1H), 2.83–2.70 (m, 1H), 1.86 (d, *J* = 12.5 Hz, 2H), 1.64 (q, *J* = 7.0 Hz, 2H), 1.50–1.39 (m, 1H), 1.32–1.20 (m, 2H); HRMS (ESI-TOF) calcd for C₁₉H₂₁BrN₆O₂S [M + H⁺] 477.0703, found 477.0789; HPLC purity, 99.2% (t_R = 3.95 min).

1-[4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)-sulfanyl]purin-9-yl]ethyl]-1-piperidyl]ethanone (28b). The title compound was prepared by the EDCI coupling method described for the preparation of **28g** using **27b** and AcOH. HRMS (ESI-TOF) calcd for $C_{21}H_{23}BrN_6O_3S$ [M + H⁺] 519.0809, found 519.0555; HPLC purity, 95.9% (t_R = 7.56 min).

1-[4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)-sulfanyl]purin-9-yl]ethyl]-1-piperidyl]butan-1-one (28c). The title compound was prepared according to the EDCI coupling method described for the preparation of **28g** using **27b** and butyric acid. ¹H NMR (400 MHz, CD₃OD) δ 8.16 (s, 1H), 7.44 (brs, 2H), 7.39 (s, 1H), 6.81 (s, 1H), 6.01 (s, 2H), 4.32 (brd, *J* = 12.4 Hz, 1H), 4.18 (t, *J* = 6.8 Hz, 2H), 3.81 (brd, *J* = 12.4 Hz, 1H), 2.86 (brt, *J* = 10.8 Hz, 1H), 2.39 (brt, *J* = 10.8 Hz, 1H), 2.24 (t, *J* = 6.8 Hz, 2H), 1.69 (q, *J* = 7.2 Hz, 2H), 1.48 (m, 2H), 1.40 (m, 1H), 1.01 (m, 1H), 0.92 (m, 1H), 0.87 (t, *J* = 7.6 Hz, 3H); HRMS (ESI-TOF) calcd for C₂₃H₂₇BrN₆O₃S [M + H⁺] 547.1122, found 547.1109; HPLC purity, 97.0% (*t*_R = 7.86 min).

[4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]cyclopropylmethanone (28d). The title compound was prepared according to the general EDCI coupling method using cyclopropanecarboxylic acid. HRMS (ESI-TOF) calcd for $C_{23}H_{25}BrN_6O_3S$ [M + H⁺] 545.0965, found 545.0956; HPLC purity, 99.9% (t_R = 5.10 min).

[4-[2-[6-Åmino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]cyclopentylmethanone (28e). The title compound was prepared according to the general EDCI coupling method using cyclopentanecarboxylic acid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.16 (s, 1H), 7.49 (s, 1H), 7.05 (s, 1H), 6.06 (s, 2H), 4.50 (d, *J* = 13.2 Hz, 1H), 4.29 (t, *J* = 7.2 Hz, 2H), 4.07 (d, *J* = 14.0 Hz, 1H), 3.07–2.98 (m, 2H), 2.57 (dd, *J* = 12.9 Hz, 3.1 Hz, 1H), 1.92–1.50 (m, 9H), 1.38–1.25 (m, 4H), 1.22–1.00 (m, 2H); LC–MS [M + H⁺] 573.2; HPLC purity, 96.6% (*t*_R = 5.68 min).

1-[4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)-sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-hydroxyethanone (28f). The title compound was prepared in 59% yield according to the general EDCI coupling method using glycolic acid. ¹H NMR (400 MHz, DMSO- d_6) δ 8.20 (s, 1H), 7.74–7.58 (brs, 2H), 7.39 (s, 1H), 6.84 (s, 1H), 6.09 (s, 2H), 4.29 (d, *J* = 12.5 Hz, 1H), 4.19 (t, *J* = 7.4 Hz, 2H), 4.07 (d, *J* = 14.4 Hz, 1H), 4.02 (d, *J* = 14.4 Hz, 1H), 3.60 (d, *J* = 13.6 Hz, 1H), 2.82 (t, *J* = 11.7 Hz, 1H), 2.56–2.44 (m, 1H), 1.74–1.67 (m, 2H), 1.61 (q, *J* = 7.0 Hz, 2H), 1.42 (m, 1H), 1.06 (m, 1H), 0.96 (m, 1H); HRMS (ESI-TOF) calcd for C₂₁H₂₃BrN₆O₄S [M + H⁺] 535.0758, found 535.0754; HPLC purity, 98.4% (t_R = 7.26 min).

(2S)-1-[4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-hydroxypropan-1-one (28g). General Procedure for EDCI Coupling Method. To a mixture of 27b (10.0 g, 21.0 mmol), HOBt (3.54 g, 23.1 mmol), L-lactic acid (2.26 g, 23.1 mmol), and NEt₃ (11.7 mL, 83.9 mmol) was added a mixture of DMF (50 mL) and THF (50 mL) at room temperature, followed by EDCI (6.02 g, 31.4 mmol). The mixture was stirred for 10 h at room temperature. Upon compeletion of reaction as judged by HPLC, water (350 mL) was added to the mixture. After being stirred for 1 h, the mixture was filtered, washed with a mixture of water and THF (50 mL, 4/1, v/v), and air-dried to afford a crude product. The crude was purified by repetitive trituration with MeOH (or hot EtOH) to **28g** (7.5 g, 65%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.16 (s, 1H), 7.44 (brs, 2H), 7.39 (s, 1H), 6.81 (s, 1H), 6.09 (s, 2H), 4.76 (d, *J* = 7.2 Hz, 1H), 4.39 (m, 1H), 4.30 (m, 1H), 4.18 (t, *J* = 7.2 Hz, 2H), 3.91 (m, 1H), 2.86 (m, 1H), 1.78–1.66 (m, 2H), 1.64–1.56 (m, 2H), 1.43 (m, 1H), 1.18–1.12 (m, 3H), 1.08 (m, 1H), 0.95 (m, 1H); HRMS (ESI-TOF) calcd for C₂₂H₂₅BrN₆O₄S [M + H⁺] 549.0914, found 549.0913; HPLC purity, 99.0% (*t*_R = 7.14 min); HPLC (Chiralcel OJ-RH column, 100% MeOH with 0.01% TEA, isocratic, 0.5 mL/min) single peak observed at 11.7 min; no peak at 7.6 min (**28h**).

(2*R*)-1-[4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-hydroxypropan-1-one (28h). The title compound was prepared in 62% yield according to the general EDCI coupling method using *R*-sodium lactate. HRMS (ESI-TOF) calcd for $C_{22}H_{25}BrN_6O_4S$ [M + H⁺] 549.0914, found 549.0899; HPLC purity, 99.0%; HPLC (Chiralcel OJ-RH column, 100% MeOH with 0.01% TEA, isocratic, 0.5 mL/min) single peak observed at 7.6 min; no peak at 11.7 min (28f).

1-[4-[2-[6-Amino-8-(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-hydroxy-2-methylpropan-1-one (28i). The title compound was prepared according to the general EDCI coupling method using 2-hydroxy-2-methylproanoic acid. LC-MS [M + H⁺] 563.1.

1-[4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)-sulfanyl]purin-9-yl]ethyl]-1-piperidyl]propane-1,2-dione (28j). The title compound was prepared according to the general EDCI coupling method using pyruvic acid. ¹H NMR (400 MHz, CDCl₃) *δ* 8.33 (s, 1H), 7.27 (s, 1H), 7.09 (s, 1H), 6.82 (s, 1H), 6.00 (s, 2H), 4.69 (bs, 2H), 4.56 (m, 1H), 4.48 (bd, *J* = 13.2 Hz, 1H), 4.26 (t, *J* = 7.6 Hz, 2H), 3.75 (bd, *J* = 13.6 Hz, 1H), 2.98 (td, *J* = 10.4, 2.8 Hz, 1H), 2.63 (bd, *J* = 12.8, 2.8 Hz, 1H), 1.87 (brt, *J* = 14.0 Hz, 2H), 1.78–1.71 (m, 2H), 1.55 (m, 1H), 1.31–1.20 (m, 2H); HRMS (ESI-TOF) calcd for C₂₂H₂₃BrN₆O₄S [M + H⁺] 547.0758, found 547.0756; HPLC purity, 97.3% ($t_{\rm R}$ = 8.09 min).

(25)-2-Amino-1-[4-[2-[6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl]sulfanyl]purin-9-yl]ethyl]-1-piperidyl]propan-1-one (28k). The title compound was prepared in 42% yield according to the general EDCI coupling method using Boc-L-alanine and subsequent deprotection of the Boc group with 4 M HCl in dioxane. ¹H NMR (400 MHz, CD₃OD) δ 8.34 (s, 1H), 7.28 (s, 1H), 7.23 (s, 1H), 6.09 (s, 2H), 4.54–4.44 (m, 2H), 4.39 (t, *J* = 7.4 Hz, 2H), 3.85 (brd, *J* = 13.2 Hz, 1H), 3.19–3.08 (m, 1H), 2.75–2.63 (m, 1H), 2.00–1.80 (m, 4H), 1.70–1.58 (m, 1H), 1.44 (dd, *J* = 14.8, 7.0 Hz, 3H), 1.35–1.13 (m, 2H); LC–MS [M + H⁺] 548.2; HPLC purity, 95.1% ($t_{\rm R}$ = 6.32 min).

(25)-2-Amino-1-[4-[2-[6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl]sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-4-methylpentan-1-one (28). The title compound was prepared from 27b with Boc-Lleucine in a manner similar to that described for 28k. ¹H NMR (400 MHz, CD₃OD) δ 8.34 (s, 1H), 7.28 (s, 1H), 7.22 (s, 1H), 6.09 (s, 2H), 4.58–4.28 (m, 4H), 3.79 (brd, *J* = 13.2 Hz, 1H), 3.13 (t, *J* = 12.8 Hz, 1H), 2.76–2.62 (m, 1H), 2.00–1.50 (m, 7H), 1.35–1.10 (m, 3H), 1.08–0.95 (m, 6H); LC–MS [M + H⁺] = 590.1.

2-Amino-1-[4-[2-[6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-methylpropan-1one (28m). The title compound was prepared in a manner similar to that described for **28k** using **27b** and *N*-Boc-2-amino-2-methylpropanoic acid. ¹H NMR (400 MHz, CD₃OD) δ 8.34 (s, 1H), 7.28 (s, 1H), 7.22 (s, 1H), 6.09 (s, 2H), 4.45–4.16 (m, 4H), 3.10–2.80 (m, 2H), 1.94 (d, *J* = 12.8 Hz, 2H), 1.84 (q, *J* = 7.0 Hz, 2H), 1.67–1.65 (m, 7H), 1.32–1.15 (m, 2H); LC–MS [M + H]⁺ = 562.0.

[4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-(dimethylamino)ethanone (28n). The title compound was prepared according to the general EDCI coupling method using 2-(dimethylamino)acetic acid. HRMS (ESI-TOF) calcd for $C_{23}H_{28}BrN_7O_3S$ [M + H⁺] 562.4980, found 562.1173; HPLC purity, 99.9% ($t_R = 6.28$ min).

[4-[2-[6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-[(25)-pyrrolidin-2-yl]methanone (280). The title compound was prepared in 35% yield in a manner similar to that described for 28k using 27b and N-Boc-L-proline. ¹H NMR (400 MHz, CD₃OD) δ 8.31 (s, 1H), 7.29 (s, 1H), 7.20 (s, 1H), 6.09 (s, 2H), 4.63 (m, 1H), 4.59 (m, 1H), 4.38 (t, *J* = 8.0 Hz, 2H), 3.87 (m, 1H), 3.40 (m, 1H), 3.13 (m, 1H), 2.73 (m, 1H), 2.49 (m, 1H), 2.10–1.82 (m, 6H), 1.65 (m, 1H), 1.30–1.16 (m, 3H), 0.88 (m, 1H); HRMS (ESI-TOF) calcd for C₂₄H₂₈BrN₇O₃S [M + H⁺] 574.1231, found 574.1234; HPLC purity, 95.4% ($t_{\rm R}$ = 6.69 min).

tert-Butyl 4-[2-(6-Amino-9H-purin-9-yl)ethyl]piperidine-1carboxylate (33a). To a mixture of adenine (32) (11.1 g, 82.1 mmol) and Cs₂CO₃ (44.60 g, 136.9 mmol) in DMF (100 mL) was added mesylate 25a (25.2 g, 82.1 mmol). After being stirred for 12 h at room temperature, the mixture was filtered and washed with CHCl₃. The combined filtrates were diluted with CHCl₃, washed with water and brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to afford a 9:1 mixture of N9 and N3 isomers (19.2 g, 82%) (LC/MS [M + H⁺] 347.1), which was used for the next step without further purification. To a clear solution of the product in NaOAc-AcOH buffer (pH 4.6) and MeOH/THF (60 mL, 1:1 v/v) was added bromine (5.13 mL, 99.8 mmol) dropwise while maintaining the temperature at ~20 °C. After being stirred for 2 h at room temperature, the mixture was quenched with sodium metabisulfite and the pH of the reaction mixture was adjusted to ~8 by addition of saturated Na₂CO₃ solution. The product portion was extracted with CH2Cl2, washed with H2O/brine, dried (Na2SO4), filtered, and concentrated in vacuo. The crude was purified by crystallization from $CH_2Cl_2/hexane$ to give 33a (16 g, 67%). $^1\!H$ NMR (400 MHz, DMSO- d_6) δ 8.13 (s, 1H), 7.5–7.38 (brs, 2H), 4.15 (t, J = 7.4 Hz, 2H), 3.95-3.84 (m, 2H), 2.74-2.33 (m, 2H), 1.73 (d, J = 12.8 Hz, 2H), 1.67 (q, J = 6.6 Hz, 2H), 1.44–1.34 (m, 10 H), 1.02 (dq, J = 8.2, 3.5 Hz, 2H); HRMS (ESI-TOF) calcd for $C_{17}H_{25}BrN_6O_2$ [M + H⁺] 425.1295, found 425.1352; HPLC purity, 98.0% ($t_{\rm R} = 5.91$ min).

tert-Butyl 4-[2-[6-Amino-8-[(5-bromo-2,3-dihydrobenzofuran-6-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carboxylate (39a). To a solution of aryl sulfide 45 (195 mg, 0.470 mmol) in THF (2.4 mL) and EtOH (0.2 mL) was added NaOEt (34 mg). The mixture was stirred for 2 h at room temperature and concentrated in vacuo. The crude sodium thiolate was dissolved in THF (2.4 mL)-EtOH (0.2 mL), and 8-bromopurine 33a was added. After heating at 70 °C for 10 h, the mixture was cooled to room temperature, diluted with EtOAc, washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. Purification of the residue by column chromatography (SiO₂, EtOAc/hexane, 50-100%) provided 39a (83 mg, 62%). ¹H NMR (CDCl₃) δ 8.36 (s, 1H) 7.40 (t, J = 0.8 Hz, 1H), 6.49 (s, 1H), 5.64–5.57 (brs, 2H), 4.56 (t, J = 8.8 Hz, 2H), 4.24 (t, J = 7.2 Hz, 2H), 4.11-3.96 (m, 2H), 3.19 (td, J = 8.8, 0.8 Hz, 2H), 2.68-2.54 (m, 2H), 1.74–1.66 (m, 5H), 1.45 (s, 9H), 1.17–1.04 (m, 2H); HRMS (ESI-TOF) calcd for $C_{25}H_{31}BrN_6O_3S$ [M + H⁺] 575.1435, found 575.1439; HPLC purity, 96.6% ($t_{\rm R} = 9.15$ min).

tert-Butyl 4-[2-[6-Amino-8-[(6-bromo-2,3-dihydro-1,4-benzodioxin-7-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carboxylate (39b). The title compound was prepared in 59% yield in a manner similar to that described for 39a. HRMS (ESI-TOF) calcd for $C_{25}H_{31}BrN_6O_4S$ [M + H⁺] 591.1384, found 591.1390; HPLC purity, 93.0% (t_R = 8.52 min).

8-[(5-Bromo-2,3-dihydrobenzofuran-6-yl)sulfanyl]-9-[2-(4-piperidyl)ethyl]purin-6-amine (40a). To a solution of of **39a** (77 mg, 0.14 mmol) in CH_2Cl_2 (2 mL) was added TFA (200 μ L) at 0 °C, and the mixture was stirred at room temperature for 2 h. Removal of solvent in vacuo and azeotropic removal of residual TFA with toluene gave the title compound (~100 mg) that was used for the next step without further purificaiton. HRMS (ESI-TOF) calcd for $C_{20}H_{23}BrN_6OS$ [M + H⁺] 475.0910, found 475.0905.

8-[(6-Bromo-2,3-dihydro-1,4-benzodioxin-7-yl)sulfanyl]-9-[2-(4-piperidyl)ethyl]purin-6-amine (40b). The title compound was prepared in a manner similar to that described for 40a. ¹H NMR (400 MHz, DMSO- d_6) δ 8.16 (s, 1H), 7.52–7.40 (broad s, 2H), 7.28 (s, 1H), 6.69 (s, 1H), 4.28–4.15 (m, 6H), 3.23 (d, J = 12.5 Hz, 2H), 2.82–2.70 (m, 2H), 1.85 (d, J = 12.5 Hz, 2H), 1.62 (q, J = 6.6 Hz, 2H), 1.48–1.36 (m, 1H), 1.33–1.20 (m, 2H); LC–MS [M + H⁺] 491.2.

4-[2-[6-Amino-8-[(5-bromo-2,3-dihydrobenzofuran-6-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carbaldehyde (34a). To solution of aryl sulfide 45 (235 mg, 0.566 mmol) in THF (2.8 mL) and EtOH (0.28 mL) was added NaOEt (41 mg, 0.57 mmol). The mixture was stirred for \sim 2 h at room temperature and concentrated in vacuo. The crude sodium thiolate was dissolved in THF (2.8 mL)-EtOH (0.28 mL), and 8-bromopurine 33b (100 mg, 0.283 mmol) was added. After being stirred for 10 h at 70 °C, the mixtue was guenched with water and the product portion was extracted with EtOAc. The combined organic layers were washed with water, brine, dried (Na_2SO_4) , filtered, and concentrated in vacuo. The residue was triturated with EtOAc to provide 34a (87 mg, 61%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.19 (s, 1H), 7.93 (s, 1H), 7.57 (s, 1H), 7.56–7.46 (brs, 2H), 6.33 (s, 1H), 4.52 (t, J = 8.0 Hz, 2H), 4.17 (t, J = 7.2 Hz, 2H), 4.07 (brd, J = 13.2 Hz, 1H), 3.60 (brd, J = 12.8 Hz, 1H), 3.17 (t, J = 8.0 Hz, 2H), 2.86 (td, J = 12.8, 2.8 Hz, 1H), 2.44 (td, J = 12.4, 3.2 Hz, 1H), 1.76–1.64 (m, 2H), 1.59 (q, J = 6.8 Hz, 2H), 1.39 (m, 1H), 0.97 (qd, J = 12.8, 4.4 Hz, 1H), 0.87 (qd, J = 12.4, 4.4 Hz, 1H); HRMS (ESI-TOF) calcd for $C_{21}H_{23}BrN_6O_2S$ [M + H⁺] 503.0859, found 503.0857; HPLC purity, 95.4% ($t_{\rm R} = 7.28$ min).

(25)-1-[4-[2-[6-Amino-8-[(5-bromo-2,3-dihydrobenzofuran-6-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-hydroxypropan-1-one (34b). The title compound was prepared in 55% yield by the EDCI coupling method described for the preparation of 34j using 40a and L-lactic acid. ¹H NMR (400 MHz, CD₃OD) δ 8.18 (s, 1H), 7.54 (s, 1H), 6.68 (s, 1H), 4.57 (t, *J* = 8.0 Hz, 2H), 4.53 (m, 1H), 4.44 (br d, *J* = 11.6 Hz, 1H), 4.29 (t, *J* = 7.6 Hz, 2H), 3.97 (br t, *J* = 14.0 Hz, 1H), 3.23 (t, *J* = 8.0 Hz, 2H), 2.97 (m, 1H), 2.58 (m, 1H), 1.88–1.76 (m, 2H), 1.75–1.67 (m, 2H), 1.55 (m, 1H), 1.31–1.25 (m, 3H), 1.24–1.04 (m, 2H); HRMS (ESI-TOF) calcd for C₂₃H₂₇BrN₆O₃S [M + H⁺] 547.1122, found 547.1126; HPLC purity, 93.3% (t_R = 7.25 min).

4-[2-[6-Amino-8-[(6-bromo-2,3-dihydrobenzofuran-5-yl)-sulfanyl]purin-9-yl]ethyl]piperidine-1-carbaldehyde (34c). The title compound was prepared from **33b** and **48** in a manner similar to that described for **34a** except that the purification was performed by preperative RP-HPLC. ¹H NMR (400 MHz, CD₃OD) δ 8.28 (s, 1H), 7.99 (s, 1H), 7.60 (s, 1H), 7.19 (s, 1H), 4.67 (t, *J* = 9.7 Hz, 2H), 4.37 (t, *J* = 7.2 Hz, 2H), 4.31 (brd, *J* = 13.2 Hz, 1H), 3.72 (brd, *J* = 13.6 Hz, 1H), 3.22 (t, *J* = 9.7 Hz, 2H), 3.10 (td, *J* = 12.8, 2.8 Hz, 1H), 2.66 (td, *J* = 12.8, 3.2 Hz, 1H), 1.98–1.85 (m, 2H), 1.79 (q, *J* = 7.2, Hz, 2H), 1.64 (m, 1H), 1.22 (qd, *J* = 11.6, 4.8 Hz, 1H), 1.13 (qd, *J* = 12.0, 4.4 Hz, 1H); HRMS (ESI-TOF) calcd for C₂₁H₂₃BrN₆O₂S [M + H⁺] 503.0859, found 503.0860; HPLC purity, 99.9% ($t_{\rm R}$ = 7.29 min).

4-[2-[6-Amino-8-(5-bromobenzofuran-6-yl)sulfanyl-purin-9-yl]ethyl]piperidine-1-carbaldehyde (34d). The title compound was prepared in 65% yield from 33b and 46 in a manner similar to that described for 34a. ¹H NMR (400 MHz, DMSO- d_6) δ 8.17 (*s*, 1H), 8.07 (*s*, 1H), 8.05 (d, J = 2.0 Hz, 1H), 7.89 (*s*, 1H), 7.48–7.43 (brs, 2H), 7.42 (d, J = 0.8 Hz, 1H), 6.95 (dd, J = 2.0, 0.8 Hz, 1H), 4.19 (t, J = 6.8 Hz, 2H), 4.03 (brd, J = 12.4, 1H), 3.55 (br d, J = 13.5 1H), 2.81 (td, J = 12.4, 2.8 Hz, 1H), 0.92 (qd, J = 12.4, 2.8 Hz, 1H), 1.67–1.55 (m, 4H), 1.37 (m, 1H), 0.92 (qd, J = 12.4, 4.0 Hz, 1H), 0.83 (qd, J = 12.4, 3.6 Hz, 1H); HRMS (ESI-TOF) calcd for $C_{21}H_{21}BrN_6O_2S$ [M + H⁺] 501.0728, found 501.0698; HPLC purity, 99.9% ($t_R = 7.42$ min).

4-[2-[6-Amino-8-(6-bromobenzofuran-5-yl)sulfanyl-purin-9-yl]ethyl]piperidine-1-carbaldehyde (34e). The title compound was prepared from **33b** and **49** in a manner similar to that described for **34a** except that the purification was performed by preperative RP-HPLC. ¹H NMR (400 MHz, CD₃OD) δ 8.31 (s, 1H), 8.09 (s, 1H), 8.05 (d, *J* = 1.2 Hz, 1H), 7.98 (s, 1H), 7.90 (d, *J* = 2.4 Hz, 1H), 6.94 (dd, *J* = 2.4, 1.2 Hz, 1H), 4.41 (t, *J* = 7.6 Hz, 2H), 4.30 (brd, *J* = 13.6, 1H), 3.71 (brd, *J* = 13.6 1H), 3.09 (td, *J* = 12.8, 2.8 Hz, 1H), 2.64 (td, *J* = 12.4, 2.8 Hz, 1H), 1.13 (qd, *J* = 12.4, 4.4 Hz, 1H); HRMS (ESI-TOF)

calcd for $C_{21}H_{21}BrN_6O_2S [M + H^+]$ 501.0728, found 501.0705; HPLC purity, 99.9% ($t_R = 7.45$ min).

4-[2-[6-Amino-8-(6-bromoindan-5-yl)sulfanylpurin-9-yl]ethyl]piperidine-1-carbaldehyde (34f). The title compound was prepared from **26d** and **25b** in a manner similar to that described for **28a**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.17 (s, 1H), 7.92 (s, 1H), 7.59 (s, 1H), 7.56–7.45 (brs, 2H), 6.91 (s, 1H), 4.16 (t, *J* = 6.8 Hz, 2H), 4.05 (m, 1H), 3.60 (m, 1H), 2.88–2.81 (m, 3H), 2.69 (t, *J* = 7.2 Hz, 2H), 2.44 (m, 1H), 1.96 (qn, *J* = 7.2 Hz, 2H), 1.72–1.61 (m, 2H), 1.61–1.55 (m, 2H), 0.98 (m, 1H), 0.96 (qd, *J* = 12.4, 4.4 Hz, 1H), 0.85 (qd, *J* = 11.6, 2.8 Hz, 1H); HRMS (ESI-TOF) calcd for C₂₂H₂₅BrN₆OS [M + H⁺] 501.10667, found 501.1067; HPLC purity, 99.0% (*t*_R = 7.7 min).

4-[2-[6-Amino-8-[(6-bromo-2,3-dihydro-1,4-benzodioxin-7-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carbaldehyde (34g). The title compound was prepared in 75% yield from **26b** and **25b** in a manner similar to that described for **28a**. ¹H NMR (400 MHz, DMSO- d_6) δ 8.17 (s, 1H), 7.93 (s, 1H), 7.62–7.44 (brs, 2H), 7.28 (s, 1H), 6.68 (s, 1H), 4.25–4.15 (m, 6H), 4.09 (d, *J* = 13.6 Hz, 1H), 3.62 (d, *J* = 13.2 Hz, 1H), 2.88 (td, *J* = 12.4, 2.4 Hz, 1H), 2.47 (td, *J* = 12.4, 2.8 Hz, 1H), 1.76–1.65 (m, 2H), 1.58 (q, *J* = 7.2 Hz, 2H), 1.39 (m, 1H), 0.99 (qd, *J* = 12.0, 4.4 Hz, 1H), 0.89 (qd, *J* = 11.2, 4.0 Hz, 1H); HRMS (ESI-TOF) calcd for C₂₁H₂₃BrN₆O₃S [M + H⁺] 519.0809, found 519.0797, HPLC purity, 99.9% (t_R = 7.19 min).

1-[4-[2-[6-Amino-8-Î(6-bromo-2,3-dihydro-1,4-benzodioxin-7-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-hydroxyethanone (**34h**). The title compound was prepared in 64% yield by the EDCI coupling method described for the preparation of **34j** using **40b** with 2-hydroxyacetic acid. ¹H NMR (400 MHz, DMOS-*d*₆) δ 8.16 (s, 1H), 7.52–7.42 (brs, 2H), 7.29 (s, 1H), 6.68 (s, 1H), 4.44 (brs, 1H), 4.29 (m, 1H), 4.27–4.15 (m, 6H), 4.07 (d, *J* = 14.4 Hz, 1H), 4.02 (d, *J* = 14.4 Hz, 1H), 3.59 (brd, *J* = 13.2 Hz, 1H), 2.80 (brt, *J* = 12.0, 1H), 2.50 (m, 1H), 1.72–1.65 (m, 2H), 1.58 (q, *J* = 6.8 Hz, 2H), 1.38 (m, 1H), 1.04 (m, 1H), 0.94 (m, 1H); HRMS (ESI-TOF) calcd for C₂₂H₂₅BrN₆O₄S [M + H⁺] 549.0914, found 549.0913; HPLC purity, 95.0% (*t*_R = 7.03 min).

(25)-1-[4-[2-[6-Amino-8-[(6-bromo-2,3-dihydro-1,4-benzo-dioxin-7-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-hydroxy-propan-1-one (34i). The title compound was prepared in 77% yield by the EDCI coupling method described for the preparation of 34j using 40b and L-lactic acid. ¹H NMR (400 MHz, DMSO- d_6) δ 8.27 (s, 1H), 8.14–7.90 (brs, 2H), 7.30 (s, 1H), 6.79 (s, 1H), 4.39 (m, 1H), 4.30 (m, 1H), 4.26–4.17 (m, 6H), 3.91 (m, 1H), 2.85 (m, 1H), 2.45 (m, 1H), 1.77–1.65 (m, 2H), 1.63–1.56 (m, 2H), 1.41 (m, 1H), 1.17–1.15 (m, 3H), 1.09–0.88 (m, 2H); HRMS (ESI-TOF) calcd for C₂₃H₂₇BrN₆O₄S [M + H⁺] 563.1071, found 563.1071; HPLC purity, 98.3% (t_R = 8.21 min).

(2R)-1-[4-[2-[6-Amino-8-[(6-bromo-2,3-dihydro-1,4-benzodioxin-7-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-hydroxypropan-1-one (34j). To a mixture of 40b (5.0 g, 10.18 mmol) in a 1:1 (v/v) mixture of DMF/THF (45 mL) were added (R)-sodium lactate (1.36 g, 12.21 mmol), HOBt (1.60 g, 12.2 mmol), and EDCI (2.90 g, 15.3 mmol) at room temperature, and the mixture was stirred overnight. Upon completion, the mixture was diluted with water (200 mL) and stirred for 15 min at room temperature. The solid was collected by filtration, washed with water, and air-dried to give the crude product that was purified by trituration with MeOH to provide 34j (89%, 5.15 g). ¹H NMR (400 MHz, CD₃OD) δ 8.28 (s, 1H), 7.27 (s, 1H), 7.23 (s, 1H), 4.55 (m, 1H), 4.48 (m, 1H), 4.36 (t, J = 7.4 Hz, 2H), 4.32-4.26 (m, 4H), 4.00 (brd, J = 14.4 Hz, 1H), 3.03 (m, 1H), 2.63 (m, 1H), 1.94-1.85 (m, 2H), 1.85-1.78 (m, 2H), 1.67-1.54 (m, 1H), 1.32 (m, 3H), 1.28-1.1 (m, 2H); HRMS (ESI-TOF) calcd for C₂₃H₂₇BrN₆O₄S [M + H⁺] 563.1071, found 563.1055; HPLC purity, 99.9% ($t_{\rm R} = 7.21$ min).

4-[2-[6-Amino-8-](6-bromo-4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carbaldehyde (34k). The title compound was prepared from 33b and 51 in a manner similar to that described for 34a. ¹H NMR (DMSO- d_c) δ 8.24 (s, 1H), 7.94 (s, 1H), 6.95 (s, 1H), 6.68 (s, 1H), 4.22–4.15 (m, 4H), 4.12–4.08 (m, 2H), 3.64–3.57 (m, 1H), 3.29–3.26 (m, 2H), 2.95– 2.87 (m, 1H), 2.86 (s, 3H), 1.86–1.40 (m, 5H), 1.34–0.80 (m, 2H); LC–MS $[M + H^+]$ 532.1.

4-[2-[6-Amino-8-[(7-bromo-4-methyl-2,3-dihydro-1,4-benzoxazin-6-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carbaldehyde (34l). The title compound was prepared from 26e and 25b in a manner similar to that described for 28a. HRMS (ESI-TOF) calcd for $C_{22}H_{26}BrN_7O_2S$ [M + H⁺] 532.1125, found 532.1119; HPLC purity, 99.9% (t_R = 7.30 min).

4-[2-[6-Amino-8-(6-bromo-1-oxoindan-5-yl)sulfanylpurin-9-yl]ethyl]piperidine-1-carbaldehyde (34m). The title compound was prepared from **26f** and **25b** in a manner similar to that described for **28a.** ¹H NMR (400 MHz, CD₃OD) δ 8.32 (s, 1H), 7.97 (s, 1H), 7.95 (s, 1H), 7.34 (s, 1H), 4.36 (t, *J* = 6.8 Hz, 2H), 4.26 (brd, *J* = 12.8 Hz, 1H), 3.68 (brd, *J* = 13.2 Hz, 1H), 3.07–2.99 (m, 3H), 2.70–2.67 (m, 2H), 2.59 (td, *J* = 12.8, 2.4 Hz, 1H), 1.88–1.74 (m, 4H), 1.57 (m, 1H), 1.15 (m, 1H), 1.06 (m, 1H); HRMS (ESI-TOF) calcd for C₂₂H₂₃BrN₆O₂S [M + H⁺] 515.0859, found 515.0850; HPLC purity, 98.1% ($t_{\rm R}$ = 7.03 min).

4-[2-[6-Amino-8-](6-bromo-2,2-difluoro-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carbaldehyde (34n). The title compound was prepared from **26c** and **25b** in a manner similar to that described for **28a**. HRMS (ESI-TOF) calcd for $C_{20}H_{19}BrF_2N_6O_3S$ [M + H⁺] 541.0464, found 541.0460; HPLC purity, 96.9% ($t_R = 7.50$ min).

4-[2-[6-Amino-8-[(6-chloro-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]piperidine-1-carbaldehyde (340). The title compound was prepared in 55% yield from **33b** and **43c** in a manner similar to that described for **34a**. ¹H NMR (DMSO-*d*₆) δ 8.21 (s, 1H), 7.94 (s, 1H), 7.29 (s, 1H), 6.91 (s, 1H), 6.11 (s, 2H), 4.25–4.19 (m, 2H), 4.12–4.05 (m, 1H), 3.66–3.60 (m, 1H), 2.99–2.85 (m, 1H), 1.90–0.95 (m, 8H); HRMS (ESI-TOF) calcd for C₂₀H₂₁ClN₆O₃S [M + H⁺] 461.1157, found 461.1156; HPLC purity, 99.9% (*t*_R = 7.11 min).

(2S)-1-[4-[2-[6-Amino-8-[(6-chloro-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]-1-piperidyl]-2-hydroxypropan-1-one (34p). The title compound was prepared in 80% yield by the EDCI coupling method described for the preparation of 34j using 40d and Llactic acid. ¹H NMR (400 MHz, DMSO- d_6) δ 8.27 (s, 1H), 7.30 (s, 1H), 6.96 (s, 1H), 6.12 (s, 2H), 4.39 (m, 1H), 4.31 (m, 1H), 4.22 (t, *J* = 7.6 Hz, 2H), 3.92 (m, 1H), 2.88 (m, 1H), 2.48 (m, 1H), 1.78–1.68 (m, 2H), 1.66–1.58 (m, 2H), 1.45 (m, 1H), 1.17–1.12 (m, 3H), 1.10–0.90 (m, 2H); HRMS (ESI-TOF) calcd for C₂₂H₂₅ClN₆O₄S [M + H⁺] 505.1419, found 505.1428; HPLC purity, 99.8% (t_R = 6.98 min).

6-[6-Amino-9-[2-(1-formyl-4-piperidyl)ethyl]purin-8-yl]sulfanyl-1,3-benzodioxole-5-carbonitrile (34q). The title compound was prepared in 22% yield from **26g** and **25b** in a manner similar to that described for **28a**. ¹H NMR (CD₃OD) δ 8.31 (s, 1H), 7.98 (s, 1H), 7.39 (s, 1H), 7.38 (s, 1H), 6.21 (s, 2H), 4.41 (t, *J* = 6.8 Hz, 2H), 4.31 (brd, *J* = 13.6 Hz, 1H), 3.71 (brd, *J* = 13.2 Hz, 1H), 3.11 (td, *J* = 12.8, 3.2 Hz, 1H), 2.67 (td, *J* = 13.2, 3.2 Hz, 1H), 1.99–1.92 (m, 2H), 1.88 (q, *J* = 7.2 Hz, 2H), 1.65 (m, 1H), 1.21 (qd, *J* = 12.4, 4.4 Hz, 1H), 1.14 (qd, *J* = 12.4, 4.0 Hz, 1H); HRMS (ESI-TOF) calcd for C₂₁H₂₁N₇O₃S [M + H⁺] 452.1499, found 452.1503; HPLC purity, 99.6% ($t_{\rm R}$ = 11.53 min).

2-Ethylhexyl 3-[(6-Bromo-1,3-benzodioxol-5-yl)sulfanyl]propanoate (43a). The title compound was prepared in 50% yield from **24a** and **52** in a manner similar to that described for **45**, step 1. ¹H NMR (400 MHz, CDCl₃) δ 7.06 (s, 1H), 6.95 (s, 1H), 6.00 (s, 2H), 4.02 (dd, *J* = 12.8, 6.0 Hz, 1H), 4.00 (dd, *J* = 12.8, 5.6 Hz, 1H), 3.11 (t, *J* = 6.8 Hz, 2H), 2.62 (t, *J* = 6.8 Hz, 2H), 1.57 (m, 1H), 1.39– 1.26 (m, 8H), 0.89 (two t, *J* = 7.2 Hz, 6H); HRMS (ESI-TOF) calcd for C₁₈H₂₅Br₆O₄S [M + H⁺] 417.0730, found 417.0713.

2-Ethylhexyl 3-[(6-Bromo-2,3-dihydro-1,4-benzodioxin-7-yl)sulfanyl]propanoate (43b). The title compound was prepared in 55% yield from **24b** and **52** in a manner similar to that described for **45**, step 1. ¹H NMR (400 MHz, CDCl₃) δ 7.12 (s, 1H), 6.97 (s, 1H), 4.25 (s, 4H), 4.02 (dd, *J* = 12.8, 6.0 Hz, 1H), 4.00 (dd, *J* = 12.8, 6.0 Hz, 1H), 3.10 (t, *J* = 7.6 Hz, 2H), 2.62 (t, *J* = 7.6 Hz, 2H), 1.56 (m, 1H), 1.39–1.26 (m, 8H), 0.89 (two t, *J* = 7.2 Hz, 6H).

2-Ethylhexyl 3-[(6-Chloro-1,3-benzodioxol-5-yl)sulfanyl]propanoate (43c). The title compound was prepared in 92% yield from **41c** and **52** in a manner similar to that described for **45**, step 1. HRMS (ESI-TOF) calcd for $C_{18}H_{25}ClO_4S$ [M + H⁺] 372.1162, found 372.1162.

2-Ethylhexyl 3-[(5-Bromo-2,3-dihydrobenzofuran-6-yl)-sulfanyl]propanoate (45). *Step 1.* 6-Bromodihydrobenzofuran (44) (2.39 g, 12.02 mmol), 3-mercaptopropionic acid 2-ethyhexyl ester (**52**) (2.76 g, 12.6 mmol), Pd₂dba₃ (165 mg, 0.180 mmol), and xantphos (279 mg, 0.481 mmol) were placed in a flask followed by degassed dioxane (40 mL) and Hünig's base (4.2 mL, 0.18 mol) under nitrogen. The mixture was heated at 100 °C for 10 h, cooled to room temperature, diluted with CH₂Cl₂, filtered, and concentrated in vacuo. The residue was purified by SiO₂ chromatography (EtOAc/hexane, 0–30%) to afford 3.1 g (83%) of 2-ethylhexyl 3-(2,3-dihydro-1-benzofuran-6-ylthio)propanoate. HRMS (ESI-TOF) calcd for C₁₉H₂₈O₃ [M + H⁺] 337.1832, found 337.1795.

Step 2. To a solution of 2-ethylhexyl 3-(2,3-dihydro-1-benzofuran-6-ylthio)propanoate (500 mg, 1.49 mmol) in AcCN (3 mL) was added HBF₄OEt₂ (204 μ L, 1.50 mmol) at -20 °C, followed by NBS (267 mg, 1.50 mmol) portionwise. The reaction mixture was slowly warmed to 5–10 °C, quenched with 10% aqueous NaHSO₃ (7 mL), and extracted with Et₂O. The combined extracts were washed with H₂O, brine, and the organic layer was dried (Na₂SO₄), filtered, and concentrated in vacuo. The residue was purified by SiO₂ chromatography (EtOAc/hexane, 0–30%) to afford **45** (0.455 g, 71%). ¹H NMR (400 MHz, CDCl₃) δ 7.35 (t, *J* = 0.8 Hz, 1H), 6.76 (s, 1H), 4.59 (t, *J* = 8.8 Hz, 2H), 4.03 (dd, *J* = 12.8, 6.0 Hz, 1H), 4.01 (dd, *J* = 12.8, 6.0 Hz, 1H), 3.19 (td, *J* = 8.8, 0.8 Hz, 2H), 3.16 (t, *J* = 7.2 Hz, 2H), 2.67 (t, *J* = 7.2 Hz, 2H), 1.56 (m, 1H), 1.39–1.25 (m, 8H), 0.89 (two t, *J* = 6.8 Hz, 6H); GC–MS (EI), *m/z* 414.

2-Ethylhexyl 3-(5-Bromobenzofuran-6-yl)sulfanylpropanoate (46). To a solution of 45 (114 mg, 0.274 mmol) in dioxane (1.7 mL) was added DDQ (81 mg, 0.36 mmol), and the mixture was heated at 100 °C. After 10 h, the mixture was cooled to room temperature, diluted with Et₂O, filtered, and concentrated in vacuo. The residue was purified by SiO₂ chromatography (EtOAc/ hexane, 0–10%) to afford **46** (92 mg, 99%). ¹H NMR (400 MHz, CDCl₃) δ 7.83 (s, 1H), 7.60 (d, *J* = 2.0 Hz, 1H), 7.56 (d, *J* = 0.8 Hz, 1H), 6.70 (dd, *J* = 2.0 Hz, 0.8 Hz, 1H), 4.03 (dd, *J* = 12.8, 6.0 Hz, 1H), 4.01 (dd, *J* = 12.8, 6.0 Hz, 1H), 3.23 (t, *J* = 7.6 Hz, 2H), 2.69 (t, *J* = 7.6 Hz, 6H); GC–MS (EI), *m/z* 412.

2-Ethylhexyl 3-[(6-Bromo-4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)sulfanyl]propanoate (51). The title compound was prepared in 56% yield (two steps) from 50 and 52 in a manner smilar to that described above for 45. GC–MS (EI), m/z 445.

ASSOCIATED CONTENT

Supporting Information

Procedures for molecular modeling, synthesis of compounds **24d–e**, and ¹H NMR spectra and HPLC traces for selected compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*For S.-H.K.: phone, 801-733-9791; e-mail, seho.kimkim@ gmail.com. For K.M.Y.: phone, 801-209-2225; e-mail, kraig. yager@gmail.com.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the analytical chemistry group of Myrexis, Inc. for analytical support.

ABBREVIATIONS USED

17-AAG, 17-allylamino-17-demethoxygeldanamycin; AcCN, acetonitrile; ADME, absorption, distribution, metabolism, and excretion; AKT, protein kinase B; Barton's base, 2-tert-butyl-1,1,3,3-tetramethylguanidine; cdc37, cell division cycle 37; CDK4, cyclin-dependent kinase 4; DDQ, 2,3-dichloro-5,6dicyano-1,4-benzoquinone; 17-DMAG, 17-desmethoxy-17-N,N-dimethylaminoethylaminogeldanamycin; EDCI, N-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; EtOAc, ethyl acetate; FP, fluorescence polarization; Her2, human epidermal growth factor receptor 2; HIF-1 α , hypoxiainducible factor 1α ; HIP, Hsp70 interacting protein; HLM, human liver microsome; HOBt, N-hydroxybenzotriazole; HOP, Hsp70-Hsp90 organizing protein; HSF1, heat shock protein 1; Hsp90, 90 kDa heat shock protein; HTS, high-throughput screening; Hünig's base, diisopropylethylamine; MDR, multidrug resistance; NSCLC, non-small-cell lung cancer; Pd₂dba₂, tris(dibenzylideneacetone)dipalladium(0); PAMPA, parallel artificial membrane permeability assay; PK, pharmacokinetic; RP-HPLC, reversed-phase high-performance liquid chromatography; SAR, structure-activity relationship; xantphos, 4,5bis(diphenylphosphino)-9,9-dimethylxanthene

REFERENCES

(1) Walter, S.; Buchner, J. Molecular chaperones—cellular machines for protein folding. *Angew. Chem., Int. Ed.* **2002**, *41*, 1098–1113.

(2) Calderwood, S. K.; Khaleque, M. A.; Sawyer, D. B.; Ciocca, D. R. Heat shock proteins in cancer: chaperones of tumorigenesis. *Trends Biochem. Sci.* **2006**, *31*, 164–172.

(3) Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer. *Nat. Rev. Cancer* 2005, *5*, 761–772.

(4) Ali, M. M. U.; Roe, S. M.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. *Nature* **2006**, 440, 1013–1017.

(5) Shiau, A. K.; Harris, S. F.; Southworth, D. R.; Agard, D. A. Structural analysis of *E. coli* hsp90 reveals dramatic nucleotidedependent conformational rearrangements. *Cell* **2006**, *127*, 329–340. (6) Workman, P. Overview: translating Hsp90 biology into Hsp90 drugs. *Curr. Cancer Drug Targets* **2003**, *3*, 297–300.

(7) (a) Yufu, Y.; Nishimura, J.; Nawata, H. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. *Leuk. Res.* **1992**, *16*, 597–605. (b) Ciocca, D. R.; Fuqua, S. A.; Lock-Lim, S.; Toft, D. O.; Welch, W. J.; McGuire, W. L. Response of human breast cancer cells to heat shock chemotherapeutic drugs. *Cancer Res.* **1992**, *52*, 3648–3654.

(8) (a) Whitesell, L.; Shifrin, S. D.; Schwab, G.; Neckers, L. M. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. *Cancer Res.* 1992, 52, 1721–1728.
(b) Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. *Proc. Natl. Acad. Sci. U.S.A.* 1994, *91*, 8324–8328.

(9) Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. *Cell* **2000**, *100*, 57–70.

(10) Sawyers, C. Targeted cancer therapy. *Nature* **2004**, *432*, 294–297.

(11) (a) Ji, H. Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy. *Cancer Sci.* **2010**, *101*, 1993. (b) Sierra, J. R.; Cepero, V.; Giordano, S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. *Mol. Cancer* **2010**, *9*, 75. (c) Goldie, J. H. Drug resistance in cancer: a perspective. *Cancer Metastasis Rev.* **2001**, *20*, 63–68.

(12) Workman, P. Altered states: selectively drugging the Hsp90 cancer chaperone. *Trends Mol. Med.* **2004**, *10*, 47–51.

(13) Weinstein, I. B.; Joe, A. Oncogene addiction. *Cancer Res.* 2008, 68, 3077–3080.

(14) Garber, K. Synthetic lethality: killing cancer with cancer. J. Natl. Cancer Inst. 2002, 94, 1666–1668.

(15) Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. *Nature* **2003**, *425*, 407–410.

(16) Chiosis, G.; Neckers, L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem. Biol. 2006, 1, 279–284.

(17) Trepel, J.; Mollapour, M.; Giaccone, G.; Neckers, L. Targeting the dynamic HSP90 complex in cancer. *Nat. Rev. Cancer* **2010**, *10*, 537–549.

(18) (a) Luo, W.; Sun, W.; Taldone, T.; Rodina, A.; Chiosis, G. Heat shock protein 90 in neurodegenerative diseases. *Mol. Neurodegener.* **2010**, *5*, 24. (b) Neef, D. W.; Jaeger, A. M.; Thiele, D. J. Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. *Nat. Rev. Drug Discovery* **2011**, *10*, 930–944.

(19) Chaudhury, S.; Welch, T. R.; Blagg, B. S. J. Hsp90 as a target for drug development. *ChemMedChem* **2006**, *1*, 1331–1340.

(20) Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. *Biochim. Biophys. Acta* **2011**, *90*, 742–755.

(21) Janin, Y. L. ATPase inhibitors of heat-shock protein 90, second season. *Drug Discovery Today* **2010**, *15*, 342–353.

(22) Porter, J. R.; Fritz, C. C.; Depew, K. M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. *Curr. Opin. Chem. Biol.* **2010**, *14*, 412–420.

(23) Biamonte, M. A.; Van de Water, R.; Arndt, J. W.; Scannevin, R. H.; Perret, D.; Lee, W.-C. Heat shock protein 90: inhibitors in clinical trials. *J. Med. Chem.* **2010**, *53*, 3–17.

(24) Kim, Y. S.; Alarcon, S. V.; Lee, S.; Lee, M.-J.; Giaccone, G.; Neckers, L.; Trepel, J. B. Update on Hsp90 inhibitors in clinical trial. *Curr. Top. Med. Chem.* **2009**, *9*, 1479–1492.

(25) Amolins, M. W.; Blagg, B. S. J. Natural product inhibitors of Hsp90: potential leads for drug discovery. *Mini-Rev. Med. Chem.* 2009, 9, 140–152.

(26) Samuni, Y.; Ishii, H.; Hyodo, F.; Samuni, U.; Krishna, M. C.; Goldstein, S.; Mitchell, J. B. Reactive oxygen species mediated hepatotoxicity induced by the Hsp90 inhibiting anti-cancer geldanamycin and its analogs. *Free Radical Biol. Med.* **2010**, *48*, 1559–1563.

(27) Cysyk, R. L.; Parker, R. J.; Barchi, J. J., Jr.; Steeg, P. S.; Hartman, N. R.; Strong, J. M. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. *Chem. Res. Toxicol.* **2006**, *19*, 376–381.

(28) Soga, S.; Shiotsu, Y.; Akinaga, S.; Sharma, S. Development of radicicol analogues. *Curr. Cancer Drug Targets* **2003**, *3*, 359–369.

(29) (a) Winssinger, N.; Barluenga, S. Chemistry and biology of resorcylic acid lactones. *Chem. Commun.* 2007, 22–36. (b) Geng, X.; Yang, Z.-Q.; Danishefsky, S. J. Synthetic development of radicicol and cycloproparadicicol: highly promising anticancer agents targeting Hsp90. *Synlett* 2004, 1325–1333.

(30) Tietze, L. F.; Bell, H. P.; Chandrasekhar, S. Natural product hybrids as new leads for drug discovery. *Angew. Chem., Int. Ed.* 2003, 42, 3996–4028.

(31) Shen, G.; Wang, M.; Welch, T. R.; Blagg, B. S. J. Design, synthesis, and structure-activity relationships for chimeric inhibitors of Hsp90. J. Org. Chem. 2006, 71, 7618–7631.

(32) (a) Taldone, T.; Chiosis, G. Purine-scaffold Hsp90 inhibitors. *Curr. Top. Med. Chem.* 2009, 9, 1436–1446. (b) Chiosis, G. Discovery and development of purine-scaffold Hsp90 inhibitors. *Curr. Top. Med. Chem.* 2006, 6, 1183–1191.

(33) He, H.; Zatorska, D.; Kim, J.; Aguirre, J.; Llauger, L.; She, Y.; Wu, N.; Immormino, R. M.; Gewirth, D. T.; Chiosis, G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. *J. Med. Chem.* **2006**, *49*, 381–390.

(34) Biamonte, M. A.; Shi, J.; Hong, K.; Hurst, D. C.; Zhang, L.; Fan, J.; Busch, D. J.; Karjian, P. L.; Maldonado, A. A.; Sensintaffar, J. L.; Yang, Y.-C.; Kamal, A.; Lough, R. E.; Lundgren, K.; Burrows, F. J.; Timony, G. A.; Boehm, M. F.; Kasibhatla, S. R. Orally active purine-based inhibitors of the heat shock protein 90. *J. Med. Chem.* **2006**, *49*, 817–828.

(35) Kasibhatla, S. R.; Hong, K.; Biamonte, M. A.; Busch, D. J.; Karjian, P. L.; Sensintaffar, J. L.; Kamal, A.; Lough, R. E.; Brekken, J.; Lundgren, K.; Grecko, R.; Timony, G. A.; Ran, Y.; Mansfield, R.; Fritz, L. C.; Ulm, E.; Burrows, F. J.; Boehm, M. F. Rationally designed highaffinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J. Med. Chem. 2007, 50, 2767-2778. (36) Zehnder, L.; Bennett, M.; Meng, J.; Huang, B.; Ninkovic, S.; Wang, F.; Braganza, J.; Tatlock, J.; Jewell, T.; Zhou, J. Z.; Burke, B.; Wang, J.; Maegley, K.; Mehta, P. P.; Yin, M.-J.; Gajiwala, K. S.; Hickey, M. J.; Yamazaki, S.; Smith, E.; Kang, P.; Sistla, A.; Dovalsantos, E.; Gehring, M. R.; Kania, R.; Wythes, M.; Kung, P.-P. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidinecontaining inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo [3,4-d] pyrimidine-6-carboxamide. J. Med. Chem. 2011, 54, 3368-3385.

(37) Ying, W.; Du, Z.; Sun, L.; Foley, K. P.; Proia, D. A.; Blackman, R. K.; Zhou, D.; Inoue, T.; Tatsuta, N.; Sang, J.; Ye, S.; Acquaviva, J.; Ogawa, L. S.; Wada, Y.; Barsoum, J.; Koya, K. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. *Mol. Cancer Ther.* **2011**, *11*, 475–484.

(38) Zhao, H.; Guo, Z. Medicinal chemistry strategies in follow-on drug discovery. *Drug Discovery Today* **2009**, *14*, 516–522.

(39) (a) Bajji, A.; Kim, S.-H.; Tangallapally, R.; Markovitz, B.; Trovato, R.; Anderson, M. B.; Wettstein, D.; Shenderovich, M. Therapeutic Compounds and Their Use in Treating Diseases and Disorders. WO 2009/065035, 2009. (b) Bajji, A.; Kim, S.-H.; Markovitz, B.; Trovato, R.; Tangallapally, R.; Anderson, M. B.; Wettstein, D.; Shenderovich, M.; Vanecko, J. A. Therapeutic Compounds and Their Use in Cancer. WO 2007/134298, 2007.

(40) Legraverend, M. Recent advances in the synthesis of purine derivatives and their precursors. *Tetrahedron* **2008**, *64*, 8585–8603.

(41) He, H.; Llauger, L.; Rosen, N.; Chiosis, G. General method for the synthesis of 8-arylsulfanyl adenine derivatives. *J. Org. Chem.* **2004**, *69*, 3230–3232.

(42) Biamonte, M. A.; Shi, J.; Hurst, D.; Hong, K.; Boehm, M. F.; Kasibhatla, S. R. Preparation of 8-(arylsulfanyl)adenines with diazonium salts under mild, aerobic conditions. *J. Org. Chem.* **2005**, 70, 717–720.

(43) Llauger, L.; He, H.; Kim, J.; Aguirre, J.; Rosen, N.; Peters, U.; Davies, P.; Chiosis, G. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. *J. Med. Chem.* **2005**, *48*, 2892–2905.

(44) (a) Takamuro, I.; Sekine, Y.; Tsuboi, Y.; Nogi, K.; Taniguchi, H.
Preparation of Pyrazolopyrimidines as a Small Conductance Potassium Channel (SK Channel) Blocking Agents. WO 2004064721, 2004.
(b) Mani, N.; Jablonowski, J. A.; Jones, T. K. A scalable synthesis of a histamine H3 receptor antagonist. J. Org. Chem. 2004, 69, 8115–8117.
(45) Brown, T. H.; Cooper, D. G. N-Hydrocarbyl-4-Substituted Piperidines, Their Preparation and Use as Calcium Blocking Agents. WO 9202502, 1992.

(46) (a) Sonesson, C.; Swanson, L.; Waters, N. Preparation of Disubstituted Phenylpiperidines/Piperazines as Modulators of Dopamine Neurotransmission. WO 2005121087, 2003. (b) Lemoine, R.; Melville, C. R.; Rotstein, D. M.; Wanner, J. Octahydropyrrolo[3,4*c*]pyrrole Derivatives as Antiviral Agents and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of HIV Infection. WO 2008034731, 2008. (c) Blake, J.; Boyd, S.; De Meese, J.; Gaudino, J. J.; Marlow, A.; Seo, J.; Thomas, A.; Tian, H. Heterobicyclic Thiophene Compounds as Tyrosine Kinase Inhibitors and Their Preparation and Use. U.S. Patent 20070197537 A1, August 23, 2007. (47) Batey, R. A.; Powell, D. A. A general synthetic method for the formation of substituted 5-aminotetrazoles from thioureas: a strategy for diversity amplication. *Org. Lett.* **2000**, *2*, 3237–3240.

(48) (a) Itoh, T.; Mase, T. A general palladium-catalyzed coupling of aryl bromides/triflates and thiols. *Org. Lett.* **2004**, *6*, 4587–4590. (b) Itoh, T.; Mase, T. A novel practical synthesis of benzothiazoles via Pd-catalyzed thiol cross-coupling. *Org. Lett.* **2007**, *9*, 3687–3689. (c) Itoh, T.; Mase, T. Practical thiol surrogates and protective groups for arylthiols for Suzuki–Miyaura conditions. J. Org. Chem. **2006**, *71*, 2203–2206.

(49) Maitro, G.; Vogel, S.; Prestat, G.; Madec, D.; Poli, G. Aryl sulfoxides via palladium-catalyzed arylation of sulfenate anions. *Org. Lett.* **2006**, *8*, 5951–5954.

(50) Oberhauser, T. A New bromination method for phenols and anisoles: NBS/HBF₄·Et₂O in AcCN. J. Org. Chem. **1997**, 62, 4504–4506.

(51) Song, Z. J.; Zhao, M.; Frey, L.; Li, J.; Tan, L.; Chen, C. Y.; Tschaen, D. M.; Tillyer, R.; Grabowski, E. J.; Volante, R.; Reider, P. J.; Kato, Y.; Okada, S.; Nemoto, T.; Sato, H.; Akao, A.; Mase, T. Practical asymmetric synthesis of a selective endothelin A receptor (ETA) antagonist. *Org. Lett.* **2001**, *3*, 3357–3360.

(52) Kim, S.-H.; Trovato, R.; Markovitz, B.; Vanecko, J.; Shenderovich, M.; Robinson, R.; McKinnon, R.; Alberts, G.; Austin, H.; Cimbora, D.; Baichwal, V.; Papac, D.; Wettstein, D.; Bajji, A.; Yager, K. M. Unpublished results.

(53) Regina, G. L.; Silvestri, R.; Artico, M.; Lavecchia, A.; Novellino, E.; Befani, O.; Turini, P.; Agostinelli, E. New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. *J. Med. Chem.* **2007**, *50*, 922–931.

(54) (a) Watson, P. S.; Jiang, B.; Scott, B. A diastereoselective synthesis of 2,4-disubstituted piperidines: scaffolds for drug discovery. *Org. Lett.* **2000**, *2*, 3679. (b) Weintraub, P. M.; Sabol, J. S.; Kane, J. M.; Borcherding, D. R. Recent advances in the synthesis of piperidones and piperidines. *Tetrahedron* **2003**, *59*, 2953.

(55) Raub, T. J. P-Glycoprotein recognition of substrates and circumvention through rational drug design. *Mol. Pharmaceutics* **2006**, *3*, 3–25.

(56) Delorme, D.; Ducharme, Y.; Brideau, C.; Chan, C.-C.; Chauret, N.; Desmarais, S.; Dubé, D.; Falgueyret, J.-P.; Fortin, R.; Guay, J.; Hamel, P.; Jones, T. R.; Lépine, C.; Li, C.; McAuliffe, M.; McFarlane, C. S.; Nicoll-Griffithh, D. A.; Riendeau, D.; Yergey, J. A.; Girard, Y. Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability. *J. Med. Chem.* **1996**, *39*, 3951–3970.

(57) (a) Hirai, G.; Watanabe, T.; Yamaguchi, K.; Miyagi, T.; Sodeoka, M. Stereocontrolled and convergent entry to CF_2 -sialosides: synthesis of CF_2 -linked ganglioside GM4. *J. Am. Chem. Soc.* **2007**, *129*, 15420–15421. (b) Prakash, G. K. S.; Zibinsky, M.; Upton, T. G.; Kashemirov, B. A.; McKenna, C. E.; Oertell, K.; Goodman, M. F.; Batra, V.; Pedersen, L. C.; Beard, W. A.; Shock, D. D.; Wilson, S. H.; Olah, G. A. Synthesis and biological evaluation of fluorinated deoxynucleotide analogs based on bis-(difluoromethylene)triphosphoric acid. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 15693– 15698.

(58) Immormino, R. M.; Kang, Y.; Chiosis, G.; Gewirth, D. T. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. *J. Med. Chem.* **2006**, *49*, 4953–4960.

(59) Zhang, L.; Fan, J.; Vu, K.; Hong, K.; Le Brazidec, J. -Y.; Shi, J.; Biamonte, M.; Busch, D. J.; Lough, R. E.; Grecko, R.; Ran, Y.; Sensintaffar, J. L.; Kamal, A.; Lundgren, K.; Burrows, F. J.; Mansfield, R.; Timony, G. A.; Ulm, E. H.; Kasibhatla, S. R.; Boehm, M. F. 7'-Substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors. *J. Med. Chem.* **2006**, *49*, 5352–5362.

(60) Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design. J. Med. Chem. 2011, 54, 2529–2591.

23-49. (62) Tasker, A. S.; Sorensen, B. K.; Jae, H. S.; Winn, M.; von Geldern, T. W.; Dixon, D. B.; Chiou, W. J.; Dayton, B. D.; Calzadila, S.; Hernandez, L.; Marsh, K. C.; WuWong, J. R.; Opgenorth, T. J. Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists. *J. Med. Chem.* **1997**, *40*, 322-330.

(63) Murray, M. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. *Curr. Drug Metab.* **2000**, *1*, 67–84.

(64) Trachsel, D.; Hadorn, M.; Baumberger, F. Synthesis of fluoro analogues of 3,4-(methylenedioxy)amphetamine (MDA) and its derivatives. *Chem. Biodiversity* **2006**, *3*, 326–336.

(65) Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. *Pharm. Res.* **1993**, *10*, 1093–1095.

(66) (a) Ward, K. W.; Azzarano, L. M.; Evans, C. A.; Smith, B. R. Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations. *Xenobiotica* **2004**, *34*, 353–366. (b) Ward, K. W.; Azzarano, L. M.; Evans, C. A.; Smith, B. R. Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Investigation of potential experimental and mechanistic explanations. *Xenobiotica* **2004**, *34*, 367–377.

(67) Martinez, M. L.; Amidon, G. L. A mechanistic approach to understanding the factors affecting drug absorption; a review of fundamentals. *J. Clin. Pharmacol.* **2002**, *42*, 620–643.

(68) Whitesell, L.; Bagatell, R.; Falsey, R. The stress response: implications for the clinical development of hsp90 inhibitors. *Curr. Cancer Drug Targets* **2003**, *3*, 349–358.

(69) Bagatell, R.; Paine-Murrieta, G. D.; Taylor, C. W.; Pulcini, E. J.; Akinaga, S.; Benjamin, I. J.; Whitesell, L. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. *Clin. Cancer Res.* **2000**, *6*, 3312–3318.

(70) Samlowski, W. E.; Papadopoulos, K.; Olszanski, A. J.; Cimbora, D.; Baichwal, V.; Shawbell, S.; Evans, B.; Balch, A.; Mather, G.; Beelen, A. Phase 1 Study of the Hsp90 Inhibitor MPC-3100 in Subjects with Refractory or Recurrent Cancer. Presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, November 12–16, 2011. Myrexis Inc. Web site: http://www.myriadpharma.com/images/stories/product-pipeline/mpc-3100/mpc-3100-aacr-eortc-nci-2011-a96.pdf (accessed July 02, 2012).

(71) Kim, J.; Felts, S.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. *J. Biomol. Screening* **2004**, *9*, 375–381.

(72) Xu, W.; Mimnaugh, E.; Rosser, M. F. N.; Nicchitta, C.; Marcu, M.; Yarden, Y.; Neckers, L. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. *J. Biol. Chem.* **2001**, *276*, 3702–3708.

(73) Tikhomirov, O.; Carpenter, G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. *Cancer Res.* **2003**, *63*, 39–43.